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HIV/AIDS Diagnoses Among Blacks —
Florida, 1999–2004
In 2004, Florida accounted for 11% of the total number of
acquired immunodeficiency syndrome (AIDS) cases in the
United States, ranking third behind New York and Califor-
nia. Florida also had the second-highest reported AIDS diag-
nosis rate (behind New York) (1). During 2004, non-Hispanic
blacks* accounted for 14% of the Florida population but 52%
of the 77,421 persons in Florida living with human immuno-
deficiency virus (HIV)/AIDS. This report describes trends in
diagnoses of HIV/AIDS cases that occurred among blacks
during 1999–2004 and were reported to the Florida Depart-
ment of Health.† These data indicate that, during 1999–2004,
the annual rate of HIV/AIDS diagnosis among blacks
decreased more than the rates among other racial/ethnic
groups. To examine possible explanations for this decline, HIV/
AIDS diagnosis rate trends were compared with trends in gon-
orrhea diagnosis and publicly funded HIV testing in Florida.
The results indicated that gonorrhea diagnosis rates also
National Black HIV/AIDS
Awareness Day — February 7, 2007
During 2001–2004, the estimated annual number of
cases of human immunodeficiency virus/acquired
immunodeficieny syndrome (HIV/AIDS) among blacks
decreased in the 33 states with long-term, confidential,
name-based HIV reporting (1). However, the impact of
HIV among blacks remained disproportionately high
compared with other racial/ethnic populations. Blacks
made up approximately 13% of the population in the 33
reporting states yet accounted for approximately 49% of
persons who had a diagnosis of HIV/AIDS (1). Of the
estimated 1 million persons living with HIV/AIDS in the
United States at the end of 2003, nearly half (47%) were
black (1). AIDS is a leading cause of death for blacks,
who die sooner after AIDS diagnoses than persons in other
racial/ethnic populations (1), suggesting that blacks are
more likely to receive a diagnosis late in the course of
disease or to have less access to therapies that can preserve
health and prolong life.
February 7 is National Black HIV/AIDS Awareness Day.
To address the racial disparity in occurrence of HIV/AIDS,
CDC conducts research and programs for HIV preven-
tion among blacks. Examples include partnering with
community leaders and organizations to mobilize against
HIV/AIDS, expanding the reach of effective HIV-
prevention programs (2), conducting the Minority AIDS
Research Initiative, and implementing social marketing
campaigns focused on the importance of HIV testing.
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*For this report, persons identified as white, black, Asian/Pacific Islander, or
American Indian/Alaska Native are all non-Hispanic; persons described as
Hispanic might be of any race.
†Reporting of positive HIV tests by laboratories and of HIV cases (without
AIDS) by health-care providers who diagnose or treat a case has been mandatory
since mid-1997, and reporting of AIDS cases by health-care providers who
diagnose or treat a case has been mandatory since 1983; cases from both the
private and public sectors are reported to county health departments. A case is
defined as a newly diagnosed condition; a positive test (e.g., from a publicly
funded test site) does not become a reported case until it is investigated, at
which time the case registry is searched for duplicate reports. Data on numbers
of tests conducted at publicly funded counseling and testing clinics include
both negative and positive tests and might include more than one test per person.70 MMWR February 2, 2007
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decreased among blacks in Florida during 1999–2004, whereas
the number of HIV tests increased. These findings suggest
that HIV/AIDS diagnoses in blacks might be associated with
a reduction in high-risk sexual behavior and that the
decline was not the result of less testing.
The diagnosis date for HIV/AIDS was defined as the diag-
nosis date for HIV infection, regardless of whether AIDS was
diagnosed subsequently. HIV/AIDS case data were adjusted
for reporting delays and insufficient information to enable
classification into risk-factor categories (2).§ Estimated
annual percentage changes (EAPCs) in diagnoses were calcu-
lated by Poisson regression. A z test for differences in two
parameters was used to evaluate the statistical significance of
racial/ethnic differences in EAPCs.
During 1999–2004, the HIV/AIDS diagnosis rate among
blacks in Florida decreased from 224.4 cases per 100,000
population in 1999 to 134.0 in 2004 (Table 1). This decrease
resulted in a decrease in the disparity in diagnosis rates
between blacks and Hispanics (with 47.9 cases per 100,000
population in 1999 and 46.1 in 2004) and between blacks
and whites (with 18.8 cases per 100,000 population in 1999
and 18.4 in 2004); the diagnosis rate among blacks was 11.9
times higher than that among whites in 1999 but 7.3 times
higher in 2004.¶ During 1999–2004, the rate decreased among
black, Hispanic, and white females and among black males.
The annual percentage decrease in the rate was greater among
black women (EAPC = -10.2) than white women (EAPC =
-3.3) and Hispanic women (EAPC = -2.9) (p<0.05) (Table 1).
Among blacks, the total number of diagnoses decreased from
1999 to 2004 among men and women with a history of
injection-drug use (IDU), men with a history of both male-
to-male sexual contact and IDU, and men and women with a
history of high-risk heterosexual contact (i.e., sexual contact
with a person known to be HIV infected or at high risk for
HIV infection [e.g., history of IDU or male-to-male sexual
contact]) (Table 2). The EAPC decreased more among blacks
than among whites and Hispanics in all risk-factor categories
(p<0.05) except men with a history of both male-to-male sexual
contact and IDU, among whom the difference between blacks
and Hispanics was not significant.
Data reported to the Florida Department of Health regard-
ing the number of diagnosed gonorrhea cases and publicly
§Florida Department of Health staff obtained risk information for approximately
80% of HIV/AIDS cases from medical records in hospitals and doctors’ offices
and from data collected by publicly funded HIV testing sites; in addition,
certain patients were interviewed. The remaining cases (i.e., without an identified
HIV risk factor) were statistically redistributed into categories for specified risk
factors, based on expected results of follow-up investigations.
¶The numbers of cases among Asians/Pacific Islanders and American Indians/
Alaska Natives were too small for meaningful analysis and are not included in
this report.Vol. 56 / No. 4 MMWR 71
TABLE 1. Annual rates* of newly diagnosed HIV/AIDS cases and EAPC,† by race/ethnicity and sex — Florida, 1999–2004
Rate of diagnosed HIV/AIDS cases
Characteristic 1999 2000 2001 2002 2003 2004 EAPC 95% CI§
Black, non-Hispanic 224.4 192.0 180.0 170.0 152.4 134.0  -9.1¶ -9.7 to -8.4
Male 263.5 224.1 212.3 203.9 184.5 163.7  -8.2¶ -9.1 to -7.4
Female 188.4 162.4 150.2 138.6 122.8 106.4  -10.2¶ -11.2 to -9.2
Hispanic** 47.9 49.2 50.8 51.3 47.0 46.1 -1.0†† -2.2 to 0.3
Male 73.1 76.5 78.5 81.4 74.4 74.1 -0.1†† -1.5 to 1.4
Female 21.7 20.9 22.5 20.7 19.7 17.9  -2.9¶†† -5.5 to -0.2
White, non-Hispanic 18.8 18.5 18.8 17.4 17.8 18.4 -0.8†† -1.8 to 0.19
Male 31.3 31.0 31.9 29.4 30.0 31.6 -0.3†† -1.4 to 0.8
Female 7.0 6.6 6.2 5.9 6.2 5.8  -3.3¶†† -5.7 to -0.9
* Per 100,000 population, as reported to the Florida Department of Health.
† Estimated annual percentage change.
§ Confidence interval.
¶ EAPC represented a significant trend (p<0.05).
** Might be of any race.
†† Significantly different from the corresponding EAPC among blacks (p<0.05).
TABLE 2. Annual number of newly diagnosed HIV/AIDS cases* and EAPC,† by race/ethnicity and risk-factor category — Florida, 1999–2004
No. of diagnosed HIV/AIDS cases
Risk-factor category 1999 2000 2001 2002 2003 2004 EAPC 95% CI§
Male-to-male sexual contact
Black, non-Hispanic 957 843 1,001 1,016 910 845 -1.2 -2.7 to 0.4
Hispanic¶ 632 708 737 807 759 840 5.0**†† 3.2 to 6.8
White, non-Hispanic 1,283 1,350 1,424 1350 1,433 1,527 2.9**†† 1.6 to 4.2
Injection-drug use (IDU)
Black, non-Hispanic 781 665 527 461 409 386 -14.0** -15.8 to -12.2
Male 449 428 315 291 265 264 -11.6** -13.9 to -9.3
Female 332 237 212 170 144 122 -17.9** -20.7 to -15.1
Hispanic 173 183 174 165 133 129  -6.5**†† -10.0 to -3.0
Male 127 140 131 136 101 89 -6.9**†† -10.8 to -2.8
Female 45 42 43 29 32 40 -5.0†† -11.9 to 2.5
White, non-Hispanic 267 266 249 227 206 187  -7.1**†† -9.9 to -4.2
Male 141 127 137 115 100 94 -7.8** -11.7 to -3.8
Female 126 139 112 111 107 93 -6.3**†† -10.4 to -2.1
Male-to-male sexual contact and IDU
Black, non-Hispanic 120 114 106 85 94 72 -8.9** -13.2 to -4.5
Hispanic 39 39 46 40 38 38 -1.0 -8.1 to 6.6
White, non-Hispanic 119 94 91 92 106 110 -0.2†† -4.7 to 4.5
High-risk heterosexual contact§§
Black, non-Hispanic 3,481 3,072 2,840 2,714 2,517 2,202 -8.0** -8.9 to -7.2
Male 1,458 1,226 1,107 1,073 989 869 -9.0** -10.3 to -7.7
Female 2,023 1,846 1,733 1,641 1,528 1,333 -7.4** -8.4 to -6.3
Hispanic 388 390 452 473 465 447 3.6**†† 1.3 to 6.0
Male 152 154 188 195 196 203 6.3**†† 2.7 to 10.1
Female 235 236 264 279 268 244 1.8†† -1.2 to 4.8
White, non-Hispanic 400 369 390 346 392 412 0.6†† -1.7 to 3.1
Male 130 111 120 102 119 135 0.7†† -3.5 to 5.2
Female 270 257 270 244 273 277 0.6†† -2.2 to 3.6
* Diagnosed HIV/AIDS cases as reported to the Florida Department of Health, with numbers of cases reported without an HIV risk factor redistributed into
categories for specified risk factors, based on expected results of follow-up investigations.
† Estimated annual percentage change.
§ Confidence interval.
¶ Might be of any race.
** EAPC represented a significant trend (p<0.05).
†† Significantly different from the corresponding EAPC among blacks (p<0.05).
§§ Sexual contact with a person known to be HIV infected or at high risk for HIV infection (e.g., history of IDU or male-to-male sexual contact).
funded HIV tests indicated that, during 1999–2004, when
HIV/AIDS diagnosis rates significantly decreased among
blacks, gonorrhea rates also significantly decreased among
black males (EAPC = -8.7, 95% confidence interval
[CI] = -9.2 to -8.2) and black females (EAPC = -7.4,
CI = -7.9 to -6.8) (Table 3). Conversely, during 1999–2004,
the annual number of publicly funded HIV tests in Florida
increased significantly among blacks, from 81,101 tests in 199972 MMWR February 2, 2007
to 105,072 in 2004 (EAPC = 5.7, CI = 5.5–5.9), among whites,
from 108,680 tests in 1999 to 114,103 in 2004 (EAPC = 1.7,
CI = 1.6–1.9), and among Hispanics, from 32,050 tests in
1999 to 64,472 in 2004 (EAPC = 15.3, CI = 15.0–15.5).
Reported by: S Lieb, MPH, M LaLota, MPH, T Liberti, L Maddox,
MPH, D Thompson, MPH, Florida Dept of Health. R Selik, MD, Div
of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis,
STDs, and Tuberculosis Prevention (proposed), CDC.
Editorial Note: In Florida, as in most of the United States
(1), HIV/AIDS rates are higher among blacks than among
any other racial/ethnic population. However, the results of
this study indicate that the HIV/AIDS diagnosis rate in Florida
decreased more among blacks than among other racial/ethnic
populations during 1999–2004. Among blacks, rates decreased
for both sexes, and the number of cases decreased in all risk-
factor categories except men with a history of male-to-male
sexual contact, among whom the number of cases increased
significantly for whites and Hispanics.
CDC encourages health departments to use multiple data
sources to develop epidemiologic profiles of populations at
risk for HIV/AIDS, which can help improve prevention and
treatment programs (3). The Florida Department of Health
has analyzed data such as those described in this report by
county and presented them to county health departments and
the Florida public for HIV-prevention planning and commu-
nity mobilization.
Trends in gonorrhea diagnosis were examined as a possible
reflection of trends in high-risk sexual behavior and because
gonorrhea typically is diagnosed soon after sexual transmis-
sion. Like HIV/AIDS diagnosis rates in Florida, gonorrhea
diagnosis rates decreased both among black males and females.
Although increases or decreases in diagnosis rates for both
HIV/AIDS and gonorrhea might reflect changes in methods
of diagnosis, treatment, or surveillance, rather than changes
in sexual behavior, the finding that gonorrhea and HIV/AIDS
diagnosis rates both decreased suggests that high-risk sexual
behavior also decreased.
The possibility that decreases in HIV/AIDS diagnoses were
a result of decreased HIV testing among blacks was not sup-
ported by data, which indicated a significant increase in test-
ing among blacks at publicly funded HIV testing sites.
Approximately 45% of all non-AIDS HIV diagnoses in Florida
were reported from these sites.
The findings in this report are subject to at least four limi-
tations. First, because retroactive reporting of HIV cases diag-
nosed before July 1997 (the implementation date of HIV
reporting) was not allowed for persons without AIDS, some
persons whose initial HIV diagnosis occurred before mid-1997
might have been misclassified with a later diagnosis date in
this analysis if they were retested for HIV during the study
period. Depending on whether the diagnosis dates were
misclassified to the study period’s early (1999–2001) or late
(2002–2004) years, the decrease in diagnoses might have been
overestimated or underestimated, respectively. Second, data
on annual numbers of HIV tests were restricted to public clin-
ics, which might have resulted in an overall underestimation
of numbers of tests or a more pronounced underestimation
for one racial/ethnic population compared with others. Third,
persons who had multiple HIV tests in a certain year might
have been counted multiple times in the annual HIV test data.
Finally, the validity of the findings might be reduced by any
inaccuracy of the adjustments for reporting delay and by
missing risk-factor information.
Trends in the diagnosis of HIV/AIDS do not necessarily
reflect trends in the transmission of HIV infection because
diagnosis trends might be affected by other factors, including
changes in testing behavior, clinical practice, or public health
surveillance. CDC plans to address these factors by supple-
menting the HIV/AIDS case surveillance system with esti-
mates of HIV incidence using a previously described serologic
testing strategy (4). Meanwhile, examining data from other
surveillance systems can assist public health professionals with
interpreting HIV/AIDS diagnosis trends, as indicated by this
report, in which multiple data sources support the finding
TABLE 3. Annual rates* of newly diagnosed gonorrhea cases and EAPC,† by race/ethnicity and sex — Florida, 1999–2004
Rate of diagnosed gonorrhea cases
Characteristic 1999 2000 2001 2002 2003 2004 EAPC 95% CI§
Black 657.9 642.7 586.2 559.0 473.0 439.6 -8.1¶ -8.4 to -7.7
Male 731.6 718.6 646.8 622.4 515.9 471.2  -8.7¶ -9.2 to -8.2
Female 589.9 572.7 530.1 500.4 433.4 410.3 -7.4¶ -7.9 to -6.8
Hispanic** 38.2 32.2 33.7 31.7 34.1 37.6 0.2 -1.2 to 1.7
Male 47.7 39.7 42.8 35.0 38.2 40.6 -3.1¶ -5.0 to -1.2
Female 28.4 24.5 24.5 28.3 29.9 34.5 5.4¶ 3.1 to 8.1
White 33.8 33.5 31.2 33.0 32.2 33.7 -0.2 -0.9 to 0.6
Male 28.4 29.7 27.8 29.3 28.3 28.6 -0.2 -1.3 to 1.0
Female 38.9 37.1 34.4 36.6 35.8 38.5 -0.2 -1.2 to 0.8
* Per 100,000 population.
† Estimated annual percentage change.
§ Confidence interval.
¶ EAPC represented a significant trend (p<0.05).
** Might be of any race.Vol. 56 / No. 4 MMWR 73
that HIV/AIDS diagnosis rates among blacks decreased in
Florida and that this decrease might have been associated with
a decrease in high-risk sexual behavior.
The continuing high rates of HIV/AIDS and gonorrhea
diagnoses among blacks and the significantly increasing num-
bers of HIV/AIDS diagnoses for white and Hispanic men with
a history of male-to-male sexual contact underscore the need
for additional and improved prevention measures. Higher rates
of HIV testing can be expected to increase the number of
HIV-infected persons who are aware of their infection,
decrease HIV transmission to others, link infected persons to
care and counseling services earlier, and ultimately reduce
progression to AIDS and death (5).
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Rift Valley Fever Outbreak — Kenya,
November 2006–January 2007
In mid-December 2006, several unexplained fatalities asso-
ciated with fever and generalized bleeding were reported to
the Kenya Ministry of Health (KMOH) from Garissa Dis-
trict in North Eastern Province (NEP). By December 20, a
total of 11 deaths had been reported. Of serum samples col-
lected from the first 19 patients, Rift Valley fever (RVF) virus
RNA or immunoglobulin M (IgM) antibodies against RVF
virus were found in samples from 10 patients; all serum speci-
mens were negative for yellow fever, Ebola, Crimean-Congo
hemorrhagic fever, and dengue viruses. The outbreak was
confirmed by isolation of RVF virus from six of the speci-
mens. Humans can be infected with RVF virus from bites of
mosquitoes or other arthropod vectors that have fed on ani-
mals infected with RVF virus, or through contact with viremic
animals, particularly livestock. Reports of livestock deaths and
unexplained animal abortions in NEP provided further evi-
dence of an RVF outbreak. On December 20, an investiga-
tion was launched by KMOH, the Kenya Field Epidemiology
and Laboratory Training Program (FELTP), the Kenya Medi-
cal Research Institute (KEMRI), the Walter Reed Project of
the U.S. Army Medical Research Unit, CDC-Kenya’s Global
Disease Detection Center, and other partners, including the
World Health Organization (WHO) and Médecins Sans
Frontières (MSF). This report describes the findings from that
initial investigation and the control measures taken in response
to the RVF outbreak, which spread to multiple additional
provinces and districts, resulting in 404 cases with 118 deaths
as of January 25, 2007.
Teams of investigators conducted patient interviews and
reviewed medical records from December 1 forward in major
health-care facilities in the districts from which cases were first
reported. The teams detected additional cases by meeting with
elders, other leaders, and health-care providers in villages where
cases had been reported and in adjacent villages. Blood samples
from patients with suspected RVF were collected and main-
tained at 39.2ºF (4.0ºC). Samples from NEP and surround-
ing areas were transported to a field laboratory established at
Garissa Provincial Hospital by CDC, KEMRI, and KMOH;
samples from other areas were sent to KEMRI laboratories in
Nairobi and to a laboratory in Malindi that was supported by
a team from Health Canada.
A suspected case was defined as acute onset of fever (>99.5ºF
[>37.5ºC]) with headache or muscle and joint pain since
December 1 in a person who had no other known cause of
acute febrile illness (e.g., malaria). A probable case was
defined as acute onset of fever in a person with unexplained
bleeding (i.e., in stool, vomit, or sputum or from gums, nose,
vagina, skin, or eyes), vision deterioration, or altered conscious-
ness. A confirmed case was defined as a suspected or probable
case with laboratory confirmation of the presence in serum of
anti-RVF virus IgM by enzyme-linked immunosorbent assay
(ELISA) or RVF virus RNA by reverse transcription–
polymerase chain reaction (RT-PCR).
The index case was reported in Garissa District in a patient
who had symptom onset on November 30, 2006. Retrospec-
tive analysis of sera collected during July–November 2006 at
Garissa Provincial Hospital revealed no evidence of earlier acute
RVF infections. As of January 25, 2007, a total of 404 cases
of RVF had been reported in Kenya with 118 deaths, a case-
fatality rate of 29%. Of the reported cases, 115 (29%) were
laboratory confirmed by anti-RVF virus IgM by ELISA (64
cases, 56%) or RT-PCR (79, 69%), including 28 cases (24%)
confirmed by both. Of the remaining 289 cases, 109 were
classified as probable.74 MMWR February 2, 2007
Of the 230 patients with available demographic informa-
tion, 140 (61%) were male (Figure 1). Patients ranged in age
from 4 to 85 years, with a median age of 27 years (30 years for
females and 25 years for males). RVF cases were reported from
three districts in NEP (Garissa [175 cases], Ijara [125], and
Wajir [26]); five districts in Coast Province (Kilifi [38], Tana
River [16], Malindi [eight], Isiolo [eight], and Taita Taveta
[one]); two districts in Central Province (Kirinyanga [two]
and Maragua [one]); one district in Rift Valley Province
(Kajiado [three]); and one from Nairobi Area (Figure 2). The
patient from Nairobi had traveled to NEP during the week
before illness onset but was hospitalized in Nairobi. Ijara
(population 79,932) and Garissa (population 420,918) dis-
tricts had the highest RVF incidence rates: 156 and 42 per
100,000 population, respectively.
Among the first 97 reported cases from Garissa and Wajir
districts with detailed epidemiologic information available, 71
(73%) met the probable case definition; 38 of the 62 patients
who provided blood samples tested positive by IgM ELISA,
RT-PCR, or both. The most frequently reported symptoms
among the 97 patients were fever (100%), headache (90%),
bleeding (76%), malaise (70%), muscle pain (62%), back pain
(60%), vomiting (56%), and joint pain (51%).
Two thirds of the 66 patients who provided information on
potential risk factors reported having an animal that was
recently ill. The most frequently reported RVF risk factors
during the 2 weeks preceding illness onset were drinking
unboiled (raw) milk (72%); living within 100 meters of a
swamp (70%); having an ill animal (67%); drinking milk from
an ill animal (59%); working as a herdsman (50%); having a
dead animal (50%); and slaughtering an animal (42%).
Approximately 9% of patients reported contact with another
ill human.
The outbreak peaked on December 24, 2006, and the num-
ber of daily cases has been declining since December 27, 2006
(Figure 3). A ban on livestock slaughtering in Garissa District
went into effect on December 27 and was expanded as RVF
was detected in additional districts. Vaccination of animals
with live, attenuated RVF vaccine began on January 8, 2007.
Prevention messages were developed in three languages
(English, Kiswhali, and Somali), and public meetings (known
as barazas) were held to spread information rapidly to the com-
munity. Messages also were disseminated via radio, a widely
used communication medium in NEP. Village elders, chiefs,
and religious leaders were consulted throughout Garissa Dis-
trict, leading to a district ban on the slaughter of livestock and
closure of the livestock market. Health-care workers were
trained to care for persons suspected to be infected with RVF virus.
Reported by: P Nguku, S Sharif, A Omar, C Nzioka, P Muthoka,
J Njau, A Dahiye, T Galgalo, J Mwihia, J Njoroge, H Limo, J Mutiso,
R Kalani, A Sheikh, J Nyikal, Kenya Ministry of Health; D Mutonga,
J Omollo, A Guracha, J Muindi, S Amwayi, D Langat, D Owiti,
A Mohammed, Kenya Field Epidemiology and Laboratory Training
Program, Kenya Ministry of Health/CDC. J Musaa, Kenya Ministry of
Livestock and Fisheries Development. R Sang, Kenya Medical Research
Institute. R Breiman, K Njenga, D Feikin, M Katz, H Burke, P Nyaga,
M Ackers, S Gikundi, V Omballa, L Nderitu, N Wamola, R Wanjala,
S Omulo, International Emerging Infections Program, Global Disease
Detection Center, CDC Kenya. J Richardson, D Schnabel, S Martin,
US Army Medical Research Unit-Kenya. D Hoel, H Hanafi, M Weiner,
US Naval Medical Research Unit No. 3, Cairo, Egypt. J Onsongo,
T Kojo, M Duale, A Hassan, M Dabaar, C Njuguna, Kenya Country
Office; M Yao, African Regional Office; T Grein, P Formenty, World
Health Organization, Geneva, Switzerland. B Telfer, Médecins Sans
Frontières Belgium; R Lepec, Médecins Sans Frontières Epicentre, Paris,
France. H Feldmann, A Grolla, Health Canada, Winnipeg, Manitoba.
S Wainwright, Animal and Plant Health Inspection Svc, US Dept of
Agriculture. Global Disease Detection Program, Coordinating Office
for Global Health; Div of Global Migration and Quarantine, Div of
Emerging Infections and Surveillance Services, National Center for
Preparedness, Detection, and Control of Infectious Diseases (proposed);
Special Pathogens Br, Div of Viral and Rickettisial Diseases, Div of
Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-
Borne and Enteric Diseases (proposed); E Lederman, E Farnon, C Rao,
BK Kapella, H Gould, EIS officers, CDC.
Editorial Note: RVF is an acute, febrile zoonotic disease caused
by Rift Valley fever virus, which belongs to the family
Bunyaviridae and genus Phlebovirus. The virus is primarily a
vector-borne zoonotic pathogen. Humans acquire RVF
through bites from infected mosquitoes or, more frequently,
through exposure to the blood, body fluids, or tissues of ani-
mals that have been bitten by infected mosquitoes. Direct
exposure to infected animals can occur during slaughter or
through veterinary and obstetric procedures. RVF was first
described in sheep in the early 20th century, and the virus was
FIGURE 1. Number of reported Rift Valley fever cases
(n = 230), by sex and age group — Kenya,  November 2006–
January 2007*
*As of January 14, 2007.
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first isolated in humans in Kenya in 1930 (1,2). In livestock,
RVF causes abortion and death. Livestock epizootics can
occur after heavy rainfall and flooding that result in hatching
of Aedes mosquitoes (thought to be the initial vector and in-
ter-epizootic reservoir of RVF) and other vectors that feed on
nearby mammals (3). Eastern Kenya experienced unusually
heavy rainfall during October–December 2006, three times
the average for that period during the preceding 8 years and
13 times the rainfall in 2005 (Kenya Meteorological
Department, unpublished data, 2007).
FIGURE 3. Number of reported Rift Valley fever cases
(n = 330), by date of illness onset — Kenya November 2006–
January 2007*
*As of January 25, 2007, for cases with known date of onset.
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Patients with RVF usually have ini-
tial signs and symptoms of influenza-
like illness; less than 8% of patients
subsequently have severe disease,
including generalized hemorrhagic syn-
drome, encephalitis, or retinitis (2). The
overall human mortality rate from RVF
has been estimated at 0.5%–1.0% of
those infected, but the rate is much
higher among those with severe disease.
The largest reported human outbreak
occurred in Kenya during 1997–1998,
in which an estimated 89,000 persons
(based on a systematic serosurvey) were
infected and 478 died; this outbreak
also was centered in NEP (3–5). Previ-
ous RVF outbreaks among humans
were not reported outside sub-Saharan
Africa until 1977–1978, when approxi-
mately 18,000 persons became ill with
RVF in Egypt, and in 2000, when
approximately 800 persons in Saudi
Arabia and 1,000 in Yemen had severe
illness (6–8).
Like the 1997–1998 outbreak, the
current outbreak was associated with heavy rainfall, which
produced massive flooding in much of Kenya, and particu-
larly in NEP. Climatic forecasting in conjunction with satel-
lite imaging of flooded areas has been suggested as a method
for predicting where and when RVF outbreaks might occur,
potentially enabling earlier interventions (9).
Most of the cases before December 20 occurred in young
men who herded livestock, perhaps because herdsmen are the
first to identify and slaughter ill animals. Later in the out-
break, the distribution of cases broadened by age and sex.
Young women also were overrepresented, perhaps because they
handle uncooked animal products at home as they prepare
meals for the family. Cases among children aged <5 years and
the elderly have been rare, probably because they rarely inter-
act with animals or handle raw animal products.
Most patients reported to KMOH had severe illness with
bleeding, which likely accounts for the 29% case-fatality rate.
Judging from previous studies, many mild, undetected RVF
virus infections likely occurred during this outbreak (5).
Additional cases of severe disease also might have occurred in
NEP but were not detected because of the inaccessibility of
many areas of the province resulting from flooding. Many
areas of NEP, including an entire division of Garissa District,
were unreachable by road from early December to mid-January.
FIGURE 2.  Number and percentage of reported Rift Valley fever cases (N = 404), by
district — Kenya, November 2006–January 2007*
* As of January 25, 2007.
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Since mid-January, RVF in livestock has been detected in
districts surrounding Nairobi, signaling occurrence of the
outbreak in new areas. Reports also have been received of live-
stock and humans with illness consistent with RVF across the
border in Somalia, where disease assessment has been ham-
pered by ongoing security concerns. Several international or-
ganizations are collaborating to control the spread of the
outbreak within Kenya and to other countries. Travelers should
take precautions when visiting RVF-affected areas. Generally,
the risk for RVF infection among travelers to Kenya is low,
unless they visit areas where an outbreak is occurring and are
bitten by infected mosquitoes or come in contact with body
fluids, uncooked tissue, or aerosols from infected livestock.
No preventive RVF medications or licensed vaccines for
humans exist. Travelers to affected areas should reduce their
risk for infection by protecting themselves from mosquito bites
and by avoiding direct contact with livestock. Specific recom-
mendations for U.S. travelers are available at http://
www.cdc.gov/travel/other/2006/rift_valley_fever_kenya.htm.
To control the outbreak, KMOH launched several inter-
ventions, some of which might have limited the public health
impact of the outbreak. A ban on the slaughter of animals
(including during Eid-ul-azha, a religious holiday) was im-
posed in NEP and strictly enforced. The Ministry of Live-
stock and Fisheries Development initiated a policy of
vaccinating apparently unaffected herds of livestock in dis-
tricts in which human or livestock RVF disease had been con-
firmed and also in adjacent districts; however, as of January
25, only a small proportion of livestock had been immunized.
Other interventions included heightened disease surveillance
among humans and animals, community mobilization, ani-
mal quarantines and restricted transport of livestock, and an
integrated vector-control strategy, including indoor residual
spraying and larviciding. RVF wards were established in which
appropriate infection-control measures were encouraged.
Timely detection of this outbreak was aided by implemen-
tation of Integrated Disease Surveillance and Response* within
most of the affected districts. A second factor contributing to
timely detection was initiation of RVF laboratory-supported
field surveillance of febrile patients at outpatient clinics in
Garissa. Ongoing epidemiologic, entomologic, and veterinary
studies related to this outbreak continue to 1) identify factors
associated with severe forms of RVF illness and poor outcomes;
2) characterize the role of specific species of mosquitoes in
transmitting, maintaining, and spreading RVF virus; 3) assess
the economic impact of the outbreak; and 4) define the
impact of livestock immunization with live, attenuated RVF
veterinary vaccine on minimizing the spread of animal and
human disease. Taking measures to decrease contact with
mosquitoes through use of repellents and bednets and avoiding
exposure to blood or tissues of animals that might be
infected are important protective measures for preventing RVF.
Livestock vaccination also can be an effective means of pre-
venting cases of human RVF if adequate vaccination
coverage and herd immunity are achieved.
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West Nile Virus Transmission
Through Blood Transfusion —
South Dakota, 2006
West Nile virus (WNV) transmission through blood trans-
fusion was first reported in 2002 (1,2), prompting rapid imple-
mentation of nationwide screening of blood donations for
WNV by 2003 (3,4). Screening strategies were developed
using minipool nucleic acid-amplification testing (MP-NAT)
based on six or 16 pooled donor samples. To improve sensi-
tivity of WNV detection, blood-collection agencies (BCAs)
later implemented enhanced screening by individual dona-
tion NAT (ID-NAT), most often used when a given trigger
threshold of positive MP-NAT results is reached during the
WNV transmission season (5,6). This approach has been
effective, resulting in the detection and interdiction of
*A strategy of the African Regional Office of WHO that aims to improve
availability and use of surveillance and laboratory data to control infectious
diseases that are the leading causes of death, disability, and illness in the region. Vol. 56 / No. 4 MMWR 77
approximately 1,400 potentially infectious blood donations
during 2003–2005 and a reduction in recognized transfusion-
transmission events (7). A total of 23 confirmed WNV
transfusion-transmitted cases were reported in 2002, before
screening was implemented; six probable or confirmed cases
were detected in 2003 after MP-NAT screening was initiated,
one was detected in 2004, and none were detected in 2005
(7). This report describes the first WNV transfusion-
transmission cases detected since the initiation of enhanced
screening strategies using ID-NAT triggering. In 2006, two
immunosuppressed patients had onset of West Nile
neuroinvasive disease (WNND) after receiving blood prod-
ucts from a single infected donor despite a negative MP-NAT
result at the time of donation. Although risk for transmission
has been substantially reduced as a result of routine MP-NAT
and triggered ID-NAT screening, clinicians should be re-
minded that transfusion-transmitted WNV infections can still
occur, and that immunosuppressed patients are more likely to
have onset of WNND.
In September 2006, the South Dakota Department of
Health (SDDH) was notified of WNND in a man aged 82
years with end-stage renal disease who had received a kidney
transplant on August 25, 2006. Four days after the transplant
surgery, the patient received a transfusion of 2 units of packed
red blood cells (PRBC) for anemia. Ten days after surgery, the
patient was discharged to a long-term–care facility and con-
tinued to receive immunosuppressive therapy, including 750
mg of mycophenolate mofetil twice daily, 125 mg of
cyclosporin twice daily, and 20 mg of prednisone daily. Twenty-
one days after surgery, he had onset of fever, lethargy, and a
peri-incisional hematoma, prompting his readmission to the
hospital. The patient was treated empirically with broad-
spectrum antimicrobial and antifungal agents. Two days after
readmission (i.e., 23 days after transplant and 19 days after
PRBC transfusion), his mental status deteriorated rapidly. The
next day, his cerebrospinal fluid (CSF) had four white blood
cells (WBC)/mm3, 46 red blood cells (RBC)/mm3; a protein
level of 58 mg/dL, and a glucose level of 67 mg/dL. Anti-
WNV immunoglobulin M (IgM) antibody was detected in
both serum and CSF by IgM antibody-capture enzyme-linked
immunosorbent assay (MAC-ELISA) performed at SDDH.
When the patient was discharged to a long-term–care facility
(36 days after his transplant surgery), his fever had resolved,
and his mental status had improved.
Because the patient had been hospitalized during the 2 weeks
before onset of his WNV-related illness, WNV transmission
by organ transplantation or blood transfusion was considered
more likely than transmission by mosquito bite. The kidney
donor’s premortem serum was negative for both anti-WNV
IgM and WNV RNA by MAC-ELISA and reverse transcription
polymerase chain reaction (RT-PCR). One other kidney trans-
plant recipient from the same organ donor had no symptoms
of WNV disease, and serum from this recipient was negative
for both anti-WNV IgM and WNV RNA. Traceback investi-
gation revealed that the patient with WNND had
received blood products from six different donors during the
8 weeks before symptom onset. No donor samples from the
time of donation were available for testing. However, all
donors consented to have serum collected and tested for anti-
WNV IgM. One donor, the source of 1 PRBC unit trans-
fused into the patient with WNND 4 days after transplant,
was IgM positive.
The implicated blood donor was a man from a rural area of
South Dakota where substantial WNV activity in birds, mos-
quitoes, and humans occurred during the 2006 transmission
season. He had not traveled outside of South Dakota during
the month before his last donation on August 4, 2006. He
did not report any symptoms consistent with WNV disease
during the 2 weeks before this donation or during the 3 sub-
sequent months. Because the BCA that collected the dona-
tion did not conduct routine screening for WNV, a sample of
the donor’s blood was sent for screening at an out-of-state
BCA, where the MP-NAT test result for six pooled samples,
including his donation, was negative. The out-of-state BCA
had a policy of triggering ID-NAT after two WNV-positive
MP-NAT results and more than one positive in 500 results
during a rolling 7-day period. Two positive MP-NAT results
had been detected by the testing BCA during the month
before this donation; however, the positive results occurred
more than 7 days apart and therefore did not trigger ID-NAT
testing.
After identification of the IgM-positive donor, the platelet
and fresh frozen plasma (FFP) co-components from his whole
blood donation were traced. The platelet unit had been dis-
carded without being transfused. The FFP unit had been trans-
fused on August 10, 2006, into a man aged 60 years who had
received a kidney transplant in 2001 for end-stage renal dis-
ease attributed to insulin-dependent diabetes mellitus. On the
same day as the transfusion, he had undergone surgical repair
of a spinal fracture caused by a fall. He received a transfusion
of 15 blood products, including 6 units of FFP, one of which
was from the blood donor described in this report. One week
after surgery, he was discharged to a rehabilitation facility,
where he continued to receive immunosuppressive therapy,
including 4 mg tacrolimus twice daily and 500 mg
mycophenolate mofetil three times daily. Eleven days after the
surgery, he had onset of fever and was treated empirically with
antimicrobial and antifungal agents. Fifteen days after sur-
gery, he had onset of tremors, encephalopathy, and acute left
arm paralysis unexplained by his previous injury but78 MMWR February 2, 2007
*Information available at http://www.aabb.org/content/programs_and_services/
west_nile_virus_study/wnvstudy.htm.
consistent with WNV-associated myelitis. The patient’s CSF
had four WBC/mm3, zero RBC/mm3, a protein level of 171
mg/dL, and a glucose level of 52 mg/dL. Anti-WNV IgM
was detected in the CSF by MAC-ELISA at SDDH. The
patient’s fever, tremors, and encephalopathy resolved, but his
left arm paralysis persisted at the time of transfer to an out-of-
state hospital 5 days after symptom onset (20 days after sur-
gery). Three months later, the patient remained in a
long-term–care facility.
Reported by: L Kightlinger, PhD, South Dakota Dept of Health.
SM Brend, MPH, Iowa Dept of Health. J Gorlin, MD, Memorial Blood
Centers, St. Paul; MM Kemperman, Minnesota Dept of Health.
MJ Kuehnert, MD, National Center for Preparedness, Detection, and
Control of Infectious Diseases (proposed); JJ Sejvar, MD, GL Campbell,
MD, National Center for Zoonotic, Vector-Borne, and Enteric Diseases
(proposed); EC Farnon, MD, KD Ellingson, PhD, EIS officers, CDC.
Editorial Note: This report describes two cases of probable
transfusion-transmitted WNV from a common blood donor
despite a negative MP-NAT result at the time of donation.
The source of infection cannot be proven because blood
samples or co-components from the implicated donation were
unavailable for testing; however, evidence of WNND in two
recipients of blood products from a common donor with
serologic evidence of recent infection makes WNV transfusion-
transmission probable. Because these two transfusion recipi-
ents were hospitalized for at least 2 weeks each before onset of
WNND, neither patient was likely to have acquired infection
from a mosquito bite. Furthermore, for the patient who un-
derwent transplant surgery on August 25, transmission
through the transplanted kidney is unlikely, given that
neither the organ donor nor the other organ recipient had
evidence of WNV infection.
Nationwide blood screening for WNV has been successful
in preventing transfusion-transmitted WNV (3). However, as
with all blood donation screening, infections can be transmit-
ted to transfusion recipients on rare occasions despite nega-
tive donor test results. Although WNV transmission by blood
transfusion is rare, the cases described in this report under-
score the importance of clinical recognition, effective WNV
blood screening strategies, and investigation coordination.
Transfusion-transmitted WNND might be difficult to rec-
ognize, but physicians should consider the disease as a pos-
sible diagnosis, particularly when unexplained neurologic
complications occur in immunosuppressed patients after trans-
fusion. Both patients described in this report were kidney trans-
plant recipients who were immunosuppressed when they had
onset of WNND after receiving blood product transfusions.
Although WNND occurs in less than 1% of WNV infections
overall (the majority of which are mosquito-borne), transplant
patients who acquire WNV infections have an estimated
forty-fold greater risk for developing WNND compared with
the general population (8).
The results of this investigation highlight the potential for
false-negative MP-NAT results and the need to evaluate strat-
egies for triggering ID-NAT donor screening; however, they
also underscore the rarity of WNV transfusion-transmission
events. Since ID-NAT triggering was fully implemented after
the start of the 2004 transmission season, no transfusion-
transmitted cases had been detected until the cases described
in this report. Most false-negative MP-NAT results are caused
by low-level viremic donor samples in which WNV is unde-
tected by MP-NAT but is potentially identifiable by the more
sensitive ID-NAT. Criteria for triggering ID-NAT differ
among BCAs, but most are based on the number of positive
MP-NAT results or a threshold rate for all positive results
reached during a rolling 7-day period (5). Certain BCAs col-
lect blood and perform NAT screening on-site; however, BCAs
without the ability to screen for WNV send donor samples to
remote (sometimes out-of-state) BCAs for testing. BCAs per-
forming the testing determine when to trigger ID-NAT upon
reviewing their own results.
To enhance the sensitivity of ID-NAT triggering, BCAs are
considering the feasibility and utility of more standardized
criteria for ID-NAT triggering and methods for enhanced
communication among BCAs so that knowledge of positive
screening results can be shared. BCAs face many challenges in
WNV screening, including seasonal epidemics that are geo-
graphically unpredictable, limited resources for ID-NAT, and
coordination of blood collection and testing that might be
performed by multiple BCAs in a given geographic area. An
additional tool for sharing of donor screening results might
be useful to enhance ID-NAT triggering. The WNV
Biovigilance Network,* currently being piloted by AABB (for-
merly known as the American Association of Blood Banks) to
aggregate WNV blood donor screening results, is a model for
successful collaboration. However, timeliness of reporting must
be addressed to adapt the network for use in decisions regard-
ing ID-NAT triggering.
Public health investigations involving patients with recent
transplantation or blood transfusion are complex and often
involve multiple states and local jurisdictions. Coordination
among state and local health departments, clinicians, BCAs,
hospital blood banks, transplant centers, and CDC often is
required. Prompt reporting of suspected cases to local and
state health departments, with assistance from CDC, will
promote timely traceback investigations that can identify
additional cases and prevent further transmission.Vol. 56 / No. 4 MMWR 79
References
1. CDC. West Nile virus activity—United States, October 10–16, 2002,
and update on West Nile virus infections in recipients of blood transfu-
sions. MMWR 2002;51:929–31.
2. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile
virus through blood transfusion in the United States in 2002. N Engl J
Med 2003;349:1236–45.
3. Stramer SL, Fang CT, Foster GA, et al. West Nile virus among blood
donors in the United States, 2003 and 2004. N Engl J Med
2005;353:451–9.
4. Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply
for West Nile virus RNA by nucleic acid amplification testing. N Engl J
Med 2005;353:460–7.
5. Custer B, Busch MP, Marfin AA, Petersen LR. The cost-effectiveness of
screening the U.S. blood supply for West Nile virus. Ann Intern Med
2005;143:486–92.
6. Custer B, Tomasulo PA, Murphy EL, et al. Triggers for switching from
minipool testing by nucleic acid technology to individual-donation
nucleic acid testing for West Nile virus: analysis of 2003 data to inform
2004 decision making. Transfusion 2004;44:1547–54.
7. Montgomery SP, Brown JA, Kuehnert M, et al. Transfusion-associated
transmission of West Nile virus, United States 2003–2005. Transfusion
2006;46:2038–46.
8. Kumar D, Drebot MA, Wong SJ, et al. A seroprevalence study of West
Nile virus infection in solid organ transplant recipients. Am J Trans-
plant 2004;4:1883–8.
QuickStats
from the national center for health statistics from the national center for health statistics from the national center for health statistics from the national center for health statistics from the national center for health statistics
Prevalence of Selected Unhealthy Behavior Characteristics Among Adults
Aged >18 Years, by Race* — National Health Interview Survey,
United States, 2002–2004†
* Racial categories include persons who indicated a single race only and are consistent with the 1997 Office of
Management and Budget federal guidelines for race reporting.
† Estimates are age adjusted using the 2000 projected U.S. population as the standard population and using three
age groups: 18–44 years, 45–64 years, and >65 years. Estimates are based on household interviews of a sample
of the civilian, noninstitutionalized U.S. adult population. Denominators for each percentage exclude persons with
unknown health-behavior characteristics.
§ American Indian or Alaska Native.
¶ Native Hawaiian or other Pacific Islander.
** 95% confidence interval.
†† Smoked at least 100 cigarettes in lifetime and currently smoked.
§§ Never engaged in any light, moderate, or vigorous leisure-time physical activity.
¶¶ Defined as a body mass index (weight [kg]/height [m2]) of >30.
*** Usual number of hours of sleep during a 24-hour period. Based on data from 2004 only.
The percentage of adults with selected unhealthy behavior characteristics varied by race during 2002–2004.
Blacks and Asians had the lowest prevalence of consuming five or more alcoholic drinks in a single day; Asians
also had the lowest prevalence of current cigarette smoking and obesity. AIAN had among the highest prevalences
of consuming five or more drinks, current smoking, and obesity. Generally, physical inactivity was the most
prevalent unhealthy behavior.
SOURCE: Adams PF, Schoenborn CA. Health behaviors of adults: United States 2002–2004. Vital Health Stat
2006;10(230). Available at http://www.cdc.gov/nchs/data/series/sr_10/sr10_230.pdf.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States,
week ending January 27, 2007 (4th Week)*
5-year
Current Cum weekly Total cases reported for previous years
Disease week 2007 average† 2006 2005 2004 2003 2002 States reporting cases during current week (No.)
—: No reported cases.          N: Not notifiable.          Cum: Cumulative year-to-date counts.
* Incidence data for reporting years 2006 and 2007 are provisional, whereas data for 2002, 2003, 2004, and 2005 are finalized.
† Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5
preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
§ Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2004 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
¶ Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-
Borne, and Enteric Diseases (proposed) (ArboNET Surveillance). Data for West Nile virus are available in Table II.
** Data for H. influenzae (all ages, all serotypes) are available in Table II.
†† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed). Implementation of
HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveil-
lance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
§§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases (proposed). A total of eight cases were reported for the
2006–07 flu season.
¶¶ No measles cases were reported for the current week.
*** Data for meningococcal disease (all serogroups) are available in Table II.
††† No rubella cases were reported for the current week.
§§§ Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed).
A n t h r a x ——— 1——— 2
Botulism:
foodborne — — 0 16 19 16 20 28
i n f a n t — 2 28 78 58 77 66 9
other (wound & unspecified) — — 0 47 31 30 33 21
Brucellosis — 5 2 114 120 114 104 125
Chancroid — — 1 28 17 30 54 67
C h o l e r a — —068522
Cyclosporiasis§ 2 5 1 123 543 171 75 156 FL (2)
D i p h t h e r i a —————— 1 1
Domestic arboviral diseases§,¶:
California serogroup — — — 63 80 112 108 164
eastern equine — — — 7 21 6 14 10
Powassan — — — 1 1 1 — 1
St. Louis — — — 9 13 12 41 28
western equine ————————
Ehrlichiosis§:
human granulocytic 1 3 1 501 786 537 362 511 NY (1)
human monocytic 2 8 1 444 506 338 321 216 GA (1), CA (1)
human (other & unspecified) 2 4 0 191 112 59 44 23 MD (2)
Haemophilus influenzae,**
  invasive disease (age <5 yrs):
serotype b — — 0 9 9 19 32 34
nonserotype b — 3 2 94 135 135 117 144
unknown serotype 2 17 4 230 217 177 227 153 FL (1), AZ (1)
Hansen disease§ — 1 1 74 87 105 95 96
Hantavirus pulmonary syndrome§ —— 03 32 62 42 61 9
Hemolytic uremic syndrome, postdiarrheal§ 1 4 1 249 221 200 178 216 GA (1)
Hepatitis C viral, acute 3 22 18 807 652 713 1,102 1,835 OH (1), FL (2)
HIV infection, pediatric (age <13 yrs)†† — — 4 52 380 436 504 420
Influenza-associated pediatric mortality§,§§ —71 4 1 4 5 —NN
Listeriosis 10 28 8 774 896 753 696 665 NY (1), PA (1), OH (3), FL (2), CA (3)
Measles¶¶ —— 05 16 63 75 64 4
Meningococcal disease, invasive***:
A, C, Y, & W-135 1 7 6 225 297 — — — SD (1)
serogroup B 2 7 3 137 156 — — — IN (1), FL (1)
other serogroup — — 1 24 27 — — —
unknown serogroup 7 38 18 705 765 — — — NY (1), FL (1), CA (5)
Mumps 1 21 5 6,439 314 258 231 270 CA (1)
Plague — — — 16 8312
Poliomyelitis, paralytic ———— 1———
Poliovirus infection, nonparalytic§ — — —NNNNN
Psittacosis§ —— 02 01 61 21 21 8
Q fever§ 1 5 1 171 136 70 71 61 OR (1)
R a b i e s ,  h u m a n — —032723
Rubella††† — 1 0 8 11 10 7 18
Rubella, congenital syndrome — — 0 1 1 — 1 1
SARS-CoV§,§§§ —————— 8 N
Smallpox§ ————————
Streptococcal toxic-shock syndrome§ 1 4 3 92 129 132 161 118 PA (1)
Syphilis, congenital (age <1 yr) — 6 8 296 329 353 413 412
Tetanus — — 0 32 27 34 20 25
Toxic-shock syndrome (staphylococcal)§ 1 3 2 108 90 95 133 109 PA (1)
Trichinellosis — 1 0 13 16 5 6 14
Tularemia — — 0 85 154 134 129 90
Typhoid fever — 8 5 268 324 322 356 321
Vancomycin-intermediate Staphylococcus aureus§ ——— 3 2— N N
Vancomycin-resistant Staphylococcus aureus§ ———— 3 1 N N
Vibriosis (non-cholera Vibrio species infections)§ 15 —NNNNN F L  ( 1 )
Yellow fever ——————— 1Vol. 56 / No. 4 MMWR 81
TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. †Chlamydia refers to genital infections caused by Chlamydia trachomatis.
§Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
Chlamydia† Coccidioidomycosis Cryptosporidiosis
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 13,385 19,569 21,574 49,652 65,897 205 151 367 505 393 25 67 304 128 195
New England 427 604 1,081 1,613 1,730 — 0 0 — — — 3 22 5 47
Connecticut — 108 578 54 169 N 0 0 N N — 0 2 2 36
Maine§ —4 3 6 51 2 21 4 5 — 0 0 —— —0 6 2 4
Massachusetts 318 294 604 1,081 921 — 0 0 — — — 0 14 — 5
New Hampshire 24 39 71 144 127 — 0 0 — — — 1 5 — 1
Rhode Island§ 60 57 107 167 266 — 0 0 — — — 0 5 — —
Vermont§ 25 20 45 45 102 N 0 0 N N — 0 5 1 1
Mid. Atlantic 1,936 2,414 3,341 7,027 7,819 — 0 0 — — 2 9 31 15 36
New Jersey 177 390 562 759 1,409 N 0 0 N N — 0 3 — 1
New York (Upstate) 408 502 1,603 982 679 N 0 0 N N — 3 13 4 3
New York City 802 731 1,566 2,723 3,046 N 0 0 N N — 2 8 — 10
Pennsylvania 549 778 996 2,563 2,685 N 0 0 N N 2 4 17 11 22
E.N. Central 1,594 3,104 4,094 7,210 12,550 1 1 3 3 2 7 16 110 25 34
Illinois 709 1,002 1,410 2,357 4,043 — 0 0 — — — 2 22 — 5
Indiana 428 389 484 1,563 1,589 — 0 0 — — — 1 18 — —
Michigan 323 666 1,223 2,205 1,960 — 1 3 2 1 — 2 9 6 7
Ohio 59 658 1,424 626 3,306 1 0 2 1 1 7 5 33 18 12
Wisconsin 75 377 526 459 1,652 N 0 0 N N — 5 53 1 10
W.N. Central 932 1,187 1,471 3,364 4,456 — 0 1 2 — 2 12 77 20 14
Iowa 178 161 225 586 603 N 0 0 N N — 2 28 6 —
Kansas 284 149 284 657 495 N 0 0 N N 1 1 8 5 4
Minnesota — 247 321 56 1,018 — 0 0 — — — 3 21 1 4
Missouri 304 448 628 1,489 1,654 — 0 1 2 — 1 2 21 3 5
Nebraska§ 110 102 180 350 368 N 0 0 N N — 1 16 3 1
North Dakota 9 32 64 46 143 N 0 0 N N — 0 1 — —
South Dakota 47 51 116 180 175 N 0 0 N N — 1 7 2 —
S. Atlantic 3,790 3,788 5,413 11,978 11,518 — 0 1 — 2 13 17 67 50 45
Delaware 69 68 107 275 265 N 0 0 N N — 0 3 — —
District of Columbia 155 58 140 327 183 — 0 0 — — — 0 2 — 2
Florida 967 980 1,187 3,300 2,978 N 0 0 N N 7 7 32 26 15
Georgia 270 702 2,322 1,053 1,197 N 0 0 N N 4 5 12 18 13
Maryland§ 377 340 482 1,334 1,547 — 0 1 — 2 1 0 3 1 2
North Carolina 937 631 1,772 2,032 2,348 — 0 0 — — — 0 11 — 11
South Carolina§ 507 347 1,452 1,911 1,099 N 0 0 N N 1 1 13 2 —
Virginia§ 463 463 712 1,597 1,793 N 0 0 N N — 1 5 3 2
West Virginia 45 57 97 149 108 N 0 0 N N — 0 3 — —
E.S. Central 1,110 1,440 2,014 4,262 4,370 — 0 0 — — — 3 15 3 2
Alabama§ 119 419 760 666 1,024 N 0 0 N N — 1 12 — 1
Kentucky 347 142 691 526 795 N 0 0 N N — 1 3 2 1
Mississippi — 365 807 816 754 N 0 0 N N — 0 3 — —
Tennessee§ 644 512 612 2,254 1,797 N 0 0 N N — 1 5 1 —
W.S. Central 1,038 2,164 2,676 5,090 6,848 — 0 1 — — 1 4 44 3 5
Arkansas§ 185 154 336 630 569 N 0 0 N N — 0 2 — —
Louisiana 7 190 607 135 980 — 0 1 — — — 0 9 1 —
Oklahoma 254 248 423 897 611 N 0 0 N N 1 1 4 2 3
Texas § 592 1,457 1,904 3,428 4,688 N 0 0 N N — 1 35 — 2
Mountain 653 1,158 1,755 2,638 4,809 114 109 202 378 190 — 3 39 2 6
Arizona 467 368 881 1,541 1,411 114 105 200 378 182 — 0 3 1 2
Colorado 155 277 394 523 1,137 N 0 0 N N — 1 7 1 1
Idaho§ — 50 253 — 187 N 0 0 N N — 0 5 — —
Montana§ —4 9 1 4 31 0 0 7 0 N 0 0 N N —02 6 — 1
Nevada§ — 78 397 — 666 — 1 4 — 5 — 0 1 — —
New Mexico§ — 188 314 225 921 — 0 3 — — — 0 5 — —
Utah — 94 180 186 313 — 1 3 — 1 — 0 3 — 2
Wyoming§ 31 28 54 63 104 — 0 1 — 2 — 0 11 — —
Pacific 1,905 3,365 3,930 6,470 11,797 90 43 186 122 199 — 1 7 5 6
Alaska 68 81 152 216 249 N 0 0 N N — 0 1 — —
California 1,140 2,662 3,191 4,407 9,308 90 43 186 122 199 — 0 0 — —
Hawaii — 105 136 32 427 N 0 0 N N — 0 1 — —
Oregon§ 173 177 309 552 609 N 0 0 N N — 1 7 5 6
Washington 524 350 604 1,263 1,204 N 0 0 N N — 0 0 — —
American Samoa U 0 46 U U U 0 0 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico 236 96 198 569 270 N 0 0 N N N 0 0 N N
U.S. Virgin Islands U 6 16 U U U 0 0 U U U 0 0 U U82 MMWR February 2, 2007
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. † Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. §
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
Haemophilus influenzae, invasive
Giardiasis Gonorrhea All ages, all serotypes†
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 176 285 498 579 912 4,603 6,606 8,371 17,658 24,479 29 41 89 154 183
New England 2 19 44 9 57 65 97 179 279 304 — 2 12 11 7
Connecticut — 0 25 — — — 26 123 17 45 — 0 8 6 —
Maine§ 13 1 4 3 1 —2 8 37 — 04 2 1
Massachusetts — 7 18 — 42 52 46 86 200 178 — 0 7 — 6
New Hampshire — 0 9 — 3 4 3 9 11 22 — 0 2 3 —
Rhode Island§ — 1 17 — — 9 9 19 45 48 — 0 2 — —
Vermont§ 13 1 2 61 1 —1 5 34 — 02——
Mid. Atlantic 24 64 108 108 190 512 641 871 1,980 2,325 5 9 21 35 54
New Jersey — 8 16 — 35 54 104 159 271 425 — 1 4 — 10
New York (Upstate) 16 25 71 49 29 123 119 286 342 245 3 3 14 6 6
New York City 3 17 30 23 64 175 175 377 686 741 1 2 6 12 17
Pennsylvania 5 15 33 36 62 160 218 299 681 914 1 3 8 17 21
E.N. Central 23 48 95 80 194 601 1,271 2,201 2,674 5,316 5 5 13 18 27
Illinois — 9 26 — 36 224 363 521 800 1,676 — 0 6 — 6
Indiana N 0 0 N N 167 159 249 681 713 2 1 10 2 2
Michigan 5 14 38 36 67 136 266 880 762 813 — 0 5 1 3
Ohio 18 15 32 39 51 29 303 701 229 1,514 3 2 6 15 10
Wisconsin — 9 24 5 40 45 130 177 202 600 — 0 3 — 6
W.N. Central 11 24 118 49 83 313 383 488 1,264 1,439 — 2 12 9 11
Iowa 2 5 15 10 15 36 37 63 138 140 — 0 1 — —
Kansas 2 3 11 7 9 84 44 95 208 157 — 0 2 3 1
Minnesota 1 0 87 1 17 — 62 87 21 249 — 0 9 — —
Missouri 6 9 28 24 29 151 194 264 779 785 — 0 5 5 9
Nebraska§ — 2 9 2 5 3 12 7 5 6 9 37 3 —0 2 1 1
N o r t h  D a k o t a — 02—— — 2 64 9 — 0 2 — —
South Dakota — 2 6 5 8 11 6 15 21 26 — 0 0 — —
S. Atlantic 36 30 57 97 53 1,646 1,620 2,191 5,029 6,027 13 10 21 42 39
Delaware — 0 4 1 2 36 28 44 130 110 — 0 1 1 —
District of Columbia — 1 4 — 5 46 35 61 147 148 — 0 2 — —
Florida 26 12 15 57 — 404 455 549 1,564 1,410 6 3 9 10 7
Georgia 4 11 28 16 12 122 351 1,037 439 525 4 2 5 14 12
Maryland§ 6 4 11 13 18 128 122 183 474 677 3 1 5 14 7
North Carolina — 0 0 — — 571 296 766 1,139 2,357 — 0 9 — 2
South Carolina§ — 2 8 1 6 232 152 704 867 410 — 1 3 3 6
Virginia§ — 9 28 9 10 94 123 249 227 359 — 1 7 — 5
West Virginia — 0 6 — — 13 18 42 42 31 — 0 4 — —
E.S. Central — 10 42 11 26 434 576 869 1,704 1,811 — 2 7 4 11
Alabama§ — 6 30 6 12 37 193 313 331 487 — 0 5 2 2
Kentucky N 0 0 N N 149 55 268 230 310 — 0 1 — 1
Mississippi N 0 0 N N — 146 434 294 355 — 0 1 — —
Tennessee§ — 4 12 5 14 248 191 238 849 659 — 1 4 2 8
W.S. Central 7 6 18 15 4 400 901 1,279 2,193 3,009 2 1 25 9 6
Arkansas§ 3 2 10 4 — 86 83 142 327 389 — 0 2 — 1
Louisiana — 0 6 1 — 8 125 354 106 589 — 0 3 1 —
Oklahoma 4 2 11 10 4 107 90 184 327 209 2 1 24 8 5
Texas § N 0 0 N N 199 579 932 1,433 1,822 — 0 2 — —
Mountain 24 28 68 63 92 131 245 429 615 1,160 4 4 9 17 18
Arizona 9 3 9 16 11 106 92 198 356 317 2 2 6 9 3
Colorado 10 9 33 24 25 25 72 92 157 324 2 1 4 5 9
Idaho§ 1 3 12 8 14 — 2 20 — 13 — 0 1 1 1
Montana§ —2 1 1 1 5 —3 2 0 45 — 00——
Nevada§ — 1 9 — 4 — 21 135 — 244 — 0 1 — —
New Mexico§ — 1 6 1 5 — 31 65 53 173 — 0 2 — 3
Utah 4 7 25 12 27 — 17 26 40 65 — 0 4 2 2
Wyoming§ —1 4 1 1 —2 6 5 1 9 — 01——
Pacific 49 57 98 147 213 501 789 971 1,920 3,088 — 2 8 9 10
Alaska 1 1 17 6 2 11 10 27 27 33 — 0 2 4 2
California 35 39 68 99 168 340 649 833 1,493 2,588 — 0 5 — —
Hawaii 1 1 4 6 6 — 16 30 9 82 — 0 1 — —
Oregon§ 3 8 12 25 36 23 28 46 77 115 — 1 6 5 8
Washington 9 7 22 11 1 127 77 142 314 270 — 0 1 — —
American Samoa U 0 0 U U U 0 2 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 3 15 1 1 6 5 13 19 32 — 0 2 — —
U.S. Virgin Islands U 0 0 U U U 0 5 U U U 0 0 U UVol. 56 / No. 4 MMWR 83
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. †Data for acute hepatitis C, viral are available in Table I. §Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
                                                                                    Hepatitis (viral, acute), by type†
AB Legionellosis
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks   Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 19 63 117 76 264 29 85 130 129 266 20 47 107 75 99
New England —2 2 0 12 5 —1 8 2 1 6 — 2 1 2 1 7
Connecticut — 1 2 — 1 — 0 3 — 7 — 0 9 — 1
Maine§ —0 2 — 1 —0 2—1 — 02— 1
Massachusetts — 0 5 — 18 — 0 5 — 5 — 0 4 — 4
New Hampshire — 0 16 1 4 — 0 1 — 3 — 0 1 — —
Rhode Island§ —0 2 — — —0 4 2 — — 06——
Vermont§ —0 2 — 1 —0 1— — — 02 1 1
Mid. Atlantic — 7 18 6 24 1 8 20 14 46 2 14 53 18 35
New Jersey — 1 5 — 8 — 2 8 — 17 — 2 11 2 6
New York (Upstate) — 1 8 — 3 — 1 5 1 1 1 6 30 4 3
New York City — 2 10 3 9 — 2 5 — 10 — 2 16 — 10
Pennsylvania — 1 5 3 4 1 3 9 13 18 1 5 19 12 16
E.N. Central 4 6 1 3 9 2 27 8 1 6 3 1 3 13 8 2 6 1 7 1 2
Illinois — 1 4 — 3 — 1 7 — 5 — 0 2 — 5
Indiana — 0 8 — 1 — 0 7 — — 1 0 5 1 —
Michigan 2 2 7 6 10 — 3 6 12 15 — 3 11 6 3
Ohio 2 0 4 3 6 7 2 10 16 10 2 3 19 10 3
Wisconsin — 0 4 — 2 — 0 3 3 1 — 0 3 — 1
W.N. Central 1 2 848 1 3 9 8 6 3 1 1 5 5 4
Iowa — 0 1 1 — — 0 3 1 — — 0 3 — —
Kansas — 0 5 — 4 — 0 2 — 2 — 0 2 — —
Minnesota — 0 7 — — — 0 5 — — 1 0 11 1 —
Missouri 1 1 3 3 2 1 1 6 6 4 2 0 2 4 4
Nebraska§ —0 2 — 1 —0 3 1 — — 02——
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 3 — 1 — 0 1 — — — 0 1 — —
S. Atlantic 3 9 29 16 34 12 23 42 38 86 8 9 21 24 21
Delaware — 0 2 — 1 — 1 4 — 3 — 0 2 — 1
District of Columbia — 0 1 — 1 — 0 2 — — — 0 5 — —
Florida 2 4 13 11 18 10 7 16 23 34 5 3 10 11 5
Georgia 1 1 6 3 3 — 3 9 4 9 — 0 3 2 1
Maryland§ — 1 6 — 7 2 2 9 7 15 3 2 7 10 10
North Carolina — 0 20 — 3 — 0 23 — 19 — 0 5 — 3
South Carolina§ — 0 311 — 2 4 1 6 — 0 2 — —
Virginia§ —1 7 1 — —1 4 2 — — 15 1 1
West Virginia — 0 3 — — — 0 7 1 — — 0 3 — —
E.S. Central — 2 826 — 8 2 1 6 2 0 1 2 9 3 3
Alabama§ —0 3 — — —3 1 3 45 — 02——
Kentucky — 0 5 1 — — 1 5 — 5 1 0 5 3 1
Mississippi — 0 1 1 — — 1 4 — 3 — 0 2 — —
Tennessee§ —1 5 — 6 —2 7 27 — 17— 2
W.S. Central — 6 20 2 7 — 18 58 5 18 — 1 12 2 —
Arkansas§ —0 9 — 1 —1 4—3 — 01——
Louisiana — 0 4 2 — — 0 5 2 1 — 0 2 — —
Oklahoma — 0 3 — — — 0 14 — — — 0 6 — —
Texas § — 5 15 — 6 — 14 39 3 14 — 1 12 2 —
Mountain 4 5 17 12 22 — 2 9 3 13 3 2 8 5 5
Arizona 3 3 16 11 8 — 0 4 — 4 1 1 4 1 —
C o l o r a d o 11 3 1 4 —0 4—3 1 02 1 1
Idaho§ —0 2 — 2 —0 2 12 — 03— 1
Montana§ —0 3 — — —0 0— — — 01——
Nevada§ —0 1 — 3 —0 5—2 — 01— 3
New Mexico§ —0 2 — 3 —0 2 22 — 01 2—
Utah — 0 2 — 2 — 0 5 — — 1 0 6 1 —
Wyoming§ —0 1 — — —0 1— — — 00——
Pacific 71 6 5 3 2 41 1 6 81 1 2 5 2 23 0 —1 9 — 1 2
Alaska — 0 0 — — — 0 3 1 — — 0 0 — —
California 7 14 48 20 109 7 8 20 16 22 — 1 9 — 12
Hawaii — 0 3 — 2 — 0 1 — — — 0 0 — —
Oregon§ — 1 433 1 1 5 4 8 — 0 0 — —
Washington — 1 4 1 2 — 1 6 1 — — 0 0 — —
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 1 9 — 3 1 1 9 1 1 — 0 4 — —
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U84 MMWR February 2, 2007
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
Meningococcal disease, invasive†
Lyme disease Malaria All serogroups
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks   Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. † Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
United States 36 242 1,003 291 303 8 23 39 35 90 11 20 45 52 101
New England 3 19 260 14 16 — 0 6 — 3 1 1 3 2 5
Connecticut 1 8 227 5 1 — 0 3 — — — 0 2 1 2
Maine§ —2 3 4 5 3 —0 1— — — 02 1 2
Massachusetts — 0 3 — 8 — 0 3 — 2 — 0 2 — 1
New Hampshire 1 3 95 2 3 — 0 3 — — 1 0 2 — —
Rhode Island§ —0 9 3— 1 —0 1— — — 01——
Vermont§ 11 1 5 2 — —0 1—1 — 01——
Mid. Atlantic 11 142 558 174 185 — 5 14 5 21 1 3 11 7 21
New Jersey — 27 185 3 67 — 0 3 — 7 — 0 2 — 2
New York (Upstate) 7 59 250 33 12 — 1 8 3 1 1 0 4 1 2
N e w  Y o r k  C i t y —1 1 8— — —3 9 29 — 14 2 9
Pennsylvania 4 43 233 138 106 — 1 4 — 4 — 0 4 4 8
E.N. Central —1 1 1 5 3 1 2 4 1 2 7 51 2 121 2 6 1 2
I l l i n o i s — 00—— — 1 52 6 — 0 3 —6
Indiana — 0 3 — — — 0 3 — — 1 0 5 1 —
Michigan — 0 5 1 2 1 0 2 1 1 — 0 3 2 2
Ohio — 0 5 — 2 — 0 3 2 2 — 1 4 3 2
Wisconsin — 10 149 — 20 — 0 2 — 3 — 0 2 — 2
W.N. Central —5 1 6 9— — —0 1 4 34 1 14 6 4
Iowa — 1 8 — — — 0 1 1 — — 0 2 1 —
Kansas — 0 2 — — — 0 2 — — — 0 1 — —
Minnesota — 2 167 — — — 0 12 1 2 — 0 3 — —
Missouri — 0 2 — — — 0 1 — 1 — 0 2 4 1
Nebraska§ —0 2— — —0 1 1 — — 01— 3
North Dakota — 0 0 — — — 0 1 — — — 0 1 — —
South Dakota — 0 1 — — — 0 0 — 1 1 0 1 1 —
S. Atlantic 19 34 124 94 73 7 6 14 18 25 2 4 14 13 9
Delaware 3 7 28 23 23 — 0 1 — — — 0 1 — 1
District of Columbia — 0 7 — 2 — 0 2 — — — 0 1 — —
F l o r i d a 1 15 4 1 3 1 46 3 2 2 772
Georgia — 0 1 — 1 1 1 6 3 8 — 0 3 2 1
Maryland§ 14 16 81 63 41 1 1 5 5 6 — 0 2 2 3
North Carolina — 0 4 — 5 1 0 4 2 3 — 0 11 — —
South Carolina§ —0 2— — —0 2— — — 02 2—
Virginia§ 14 3 1 4 — 11 4 25 — 04— 2
West Virginia — 0 8 — — — 0 1 — — — 0 2 — —
E.S. Central —0 3— — —0 3 11 — 13 2 1
Alabama§ —0 3— — —0 2—1 — 02——
Kentucky — 0 2 — — — 0 1 — — — 0 1 — 1
Mississippi — 0 1 — — — 0 1 1 — — 0 2 2 —
Tennessee§ —0 2— — —0 2— — — 02——
W.S. Central 10 5 1 — —1 7—3 — 14 2 1
Arkansas§ —0 0— — —0 2— — — 01— 1
Louisiana — 0 0 — — — 0 1 — — — 0 2 1 —
Oklahoma — 0 0 — — — 0 2 — 1 — 0 3 — —
Texas § 10 5 1 — —1 6—2 — 03 1—
Mountain —0 3 1 — —1 6—3 — 15 1 1 0
Arizona — 0 2 — — — 0 3 — 1 — 0 3 — 2
C o l o r a d o —0 1— — —0 2—1 — 02— 6
Idaho§ —0 2— — —0 1— — — 01 1—
Montana§ —0 1 1 — —0 1— — — 01——
Nevada§ —0 1— — —0 1— — — 01——
New Mexico§ —0 1— — —0 1— — — 01——
U t a h —0 1— — —0 2—1 — 01— 2
Wyoming§ —0 1— — —0 0— — — 02——
Pacific 2 3 13 6 5 — 4 13 3 18 5 5 16 13 38
Alaska — 0 1 — — — 0 4 — 2 — 0 1 — 1
California 2 2 13 6 5 — 3 6 — 15 5 3 10 10 20
Hawaii N 0 0 N N — 0 2 — — — 0 2 1 —
Oregon§ —0 2— — —0 3 31 — 04 1 1 3
Washington — 0 1 — — — 0 4 — — — 0 5 1 4
American Samoa U 0 0 U U U 0 0 U U U 0 0 — —
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico N 0 0 N N — 0 1 — — — 0 1 — —
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 — —Vol. 56 / No. 4 MMWR 85
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. †
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
Pertussis Rabies, animal Rocky Mountain spotted fever
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 70 257 488 327 957 46 112 231 127 367 1 31 118 11 143
New England 2 21 53 5 130 7 12 26 28 28 — 0 1 — —
Connecticut — 1 9 — 9 4 4 14 19 5 — 0 0 — —
Maine† 21 1 2 5 9 —2 8 24 N 00NN
Massachusetts — 11 28 — 103 — 3 17 — 13 — 0 1 — —
New Hampshire — 2 27 — — 1 1 5 4 1 — 0 1 — —
Rhode Island† —0 1 1 — — —0 3 11 — 01——
Vermont† —1 1 4 — 9 21 5 24 — 00——
Mid. Atlantic 35 36 126 109 96 3 17 57 8 34 — 1 6 2 2
New Jersey — 4 13 1 34 — 0 0 — — — 0 1 — —
New York (Upstate) 30 18 121 80 8 — 0 0 — — — 0 2 — —
New York City — 1 8 — 5 3 1 5 8 — — 0 3 — —
Pennsylvania 5 12 26 28 49 — 16 56 — 34 — 1 4 2 2
E.N. Central 4 4 1 7 76 9 1 8 2 —2 1 8—1 — 16 1 1
Illinois — 8 17 — 62 — 0 7 — — — 0 2 — 1
Indiana — 4 23 — — — 0 2 — — — 0 1 — —
Michigan 4 12 39 12 19 — 0 5 — 1 — 0 1 1 —
Ohio — 12 25 57 70 — 0 9 — — — 0 4 — —
Wisconsin — 3 9 — 31 — 0 0 — — — 0 1 — —
W.N. Central 2 2 1 7 13 0 1 6 1 66 2 0 89 — 2 1 4 3—
Iowa — 5 15 6 51 1 1 7 1 2 — 0 1 — —
Kansas 2 5 16 18 50 3 1 5 4 2 — 0 1 1 —
Minnesota — 0 56 — — 2 0 6 2 — — 0 2 — —
Missouri — 5 14 5 45 — 1 6 1 — — 2 12 2 —
Nebraska† —1 9 11 5 —0 0— — — 05——
North Dakota — 0 9 — — — 0 7 — — — 0 0 — —
South Dakota — 0 4 — — — 0 4 — 5 — 0 0 — —
S. Atlantic 11 17 47 37 76 27 41 183 70 236 1 13 68 4 139
Delaware — 0 1 — 1 — 0 0 — — — 0 3 1 —
District of Columbia — 0 2 — — — 0 0 — — — 0 1 — —
Florida 7 4 20 16 19 3 0 167 11 167 — 0 5 — 1
Georgia — 0 3 — 3 — 5 10 — 15 1 1 5 1 —
Maryland† 32 71 02 5 —6 1 3— 1 2 — 16 1 4
North Carolina — 0 33 — 17 4 9 22 22 13 — 5 61 — 133
South Carolina† 13 1 1 21 1 —3 1 1 39 — 05— 1
Virginia† — 3 19 9 — 20 11 27 30 14 — 2 13 1 —
West Virginia — 0 9 — — — 2 7 4 6 — 0 2 — —
E.S. Central — 6 28 6 25 — 4 16 — 12 — 6 31 — 1
Alabama† —2 1 9 4 7 —1 8—2 — 2 1 1——
Kentucky — 0 5 — 2 — 0 4 — — — 0 1 — —
Mississippi — 1 4 1 6 — 0 2 — — — 0 1 — —
Tennessee† —3 1 1 11 0 —2 9— 1 0 — 4 2 2— 1
W.S. Central — 18 35 — 12 1 8 34 2 36 — 1 27 — —
Arkansas† —1 7 — 3 —0 5—1 — 0 1 0——
Louisiana — 0 2 — 1 — 0 0 — — — 0 1 — —
Oklahoma — 0 9 — — 1 1 9 2 3 — 0 18 — —
Texas † —1 6 3 2 — 8 — 7 2 9 —3 2 —0 4 — —
Mountain 16 43 88 59 230 — 3 27 2 8 — 0 5 1 —
Arizona 2 7 29 5 15 — 2 10 2 8 — 0 2 — —
Colorado 2 10 39 30 132 — 0 0 — — — 0 1 1 —
Idaho† — 1 7 5 15 — 0 25 — — — 0 3 — —
Montana† 11 9 21 2 —0 2— — — 02——
Nevada† —0 9 — 9 —0 1— — — 01——
New Mexico† 12 8 1 4 —0 2— — — 02——
Utah 8 13 39 10 37 — 0 1 — — — 0 2 — —
Wyoming† 21 8 6 6 —0 2— — — 01——
Pacific — 28 228 12 45 2 4 12 9 3 — 0 1 — —
Alaska — 1 8 8 6 1 0 4 7 1 N 0 0 N N
California — 21 225 — 5 1 3 11 2 2 — 0 1 — —
Hawaii — 1 6 — 14 N 0 0 N N N 0 0 N N
Oregon† —2 8 31 7 —0 4— — — 01——
Washington — 5 46 1 3 — 0 0 — — N 0 0 N N
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U
Guam — 0 0 — — — 0 0 — — N 0 0 N N
Puerto Rico — 0 1 — — 1 1 6 6 6 N 0 0 N N
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U86 MMWR February 2, 2007
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. †
Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
Salmonellosis Shiga toxin-producing E. coli  (STEC)† Shigellosis
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
United States 355 744 1,365 1,442 2,310 23 57 148 80 129 138 258 477 512 776
New England 32 0 8 0 4 05 3 6 1 2 1 6 17 7 —31 4 4 8 3
Connecticut — 0 19 19 479 — 0 0 — 72 — 0 3 3 64
Maine§ 1 2 10 11 3 — 0 8 — 1 — 0 2 1 —
Massachusetts — 15 53 — 47 — 1 9 — 3 — 2 11 — 17
New Hampshire 2 4 25 2 5 1 0 3 1 1 — 0 2 — 2
Rhode Island§ —1 1 0 5 — —0 2— — — 03——
Vermont§ —1 6 3 2 —0 1— — — 02——
Mid. Atlantic 38 88 190 180 232 4 6 64 11 6 2 16 43 16 61
New Jersey — 14 49 2 40 — 0 4 — 1 — 3 35 — 28
New York (Upstate) 20 26 70 53 20 — 0 4 — — 1 4 36 4 11
New York City 3 23 50 39 76 — 0 4 — — 1 4 13 9 18
Pennsylvania 15 29 67 86 96 1 2 48 6 4 — 1 6 3 4
E.N. Central 29 96 194 129 265 7 10 56 20 14 1 20 46 14 61
Illinois — 23 57 8 95 — 1 7 — — — 7 34 1 30
Indiana — 15 55 2 3 — 1 8 — 2 — 2 17 5 1
Michigan 3 18 35 22 51 — 1 6 3 3 — 3 8 — 17
Ohio 26 24 56 85 67 7 3 18 17 4 1 3 14 8 6
W i s c o n s i n — 1 62 7 1 2 4 9 —2 3 9—5 — 3 1 0— 7
W.N. Central 18 47 109 104 138 5 11 35 15 19 20 34 77 74 104
Iowa — 8 26 11 30 — 2 22 1 4 — 2 13 3 2
Kansas 4 7 16 23 14 1 0 4 3 — — 2 11 2 5
Minnesota 7 11 60 13 22 3 4 27 5 6 13 3 24 20 6
Missouri 7 14 35 38 48 — 0 0 — — 7 9 69 44 68
Nebraska§ —4 91 11 3 —0 8— — — 1 1 4— 1 5
North Dakota — 0 5 — — — 0 0 — — — 0 18 — —
South Dakota — 3 7 8 11 — 0 5 — — — 6 24 5 8
S. Atlantic 145 220 397 595 537 5 9 27 25 5 73 61 148 265 160
D e l a w a r e —3 1 0 5 5 —0 3 2 — — 02 1—
District of Columbia — 1 4 — 5 — 0 1 — — — 0 2 — 2
Florida 78 95 176 285 217 2 2 9 8 3 55 28 76 142 66
Georgia 19 32 72 117 94 — 1 7 3 2 16 23 59 113 53
Maryland§ 12 13 33 41 44 3 2 8 9 — 1 2 10 5 12
North Carolina 29 30 130 102 129 — 2 11 — 12 — 1 21 — 18
South Carolina§ 31 8 5 1 2 1 3 3 — 0 2 — 1 11 9 3 9
Virginia§ 42 0 5 7 2 3 1 0 — 0 0 —— —2 9 1 —
West Virginia — 1 16 1 — — 0 5 — — — 0 2 — —
E.S. Central 6 60 153 68 122 — 3 21 2 3 1 14 84 30 67
Alabama§ 2 24 95 23 42 — 0 5 — — 1 5 75 12 7
Kentucky 4 8 23 28 23 — 1 12 1 3 — 3 15 5 43
Mississippi — 12 42 5 21 — 0 0 — — — 2 13 1 14
Tennessee§ — 15 32 12 36 — 0 4 — 6 — 3 12 12 3
W.S. Central 8 67 179 34 79 — 1 19 2 — 10 36 138 30 43
Arkansas§ 51 5 4 6 1 3 1 8 — 0 7 1— 121 0 2 4
Louisiana — 15 42 7 20 — 0 0 — — — 1 25 3 —
Oklahoma 3 8 40 14 14 — 0 17 1 — — 2 9 2 6
Texas § — 31 102 — 27 — 2 13 — — 9 29 125 23 33
Mountain 29 50 88 118 130 1 4 17 3 5 15 25 87 37 52
A r i z o n a 1 51 7 4 1 5 4 2 8 1 2 1 3 2— 1 2 1 23 5 2 6 2 7
Colorado 9 12 30 35 44 — 1 8 — 5 2 3 15 5 7
Idaho§ 23 91 0 9 —1 7—3 — 03— 2
Montana§ —2 1 0 6 9 —0 0— — — 0 1 3 2—
Nevada§ —3 2 0 41 5 —0 5—1 — 1 2 0— 3
New Mexico§ —4 1 5 11 2 —0 1—1 — 2 1 5 3 9
U t a h 25 1 5 61 1 —1 1 4 12 1 16 1 3
Wyoming§ 11 4 2 2 —0 3— — — 0 1 9— 1
Pacific 79 114 181 174 271 — 4 17 1 — 16 34 87 42 145
Alaska — 1 4 1 9 N 0 0 N N 2 0 2 2 —
California 69 89 158 138 214 — 0 0 — N 13 29 76 28 105
Hawaii 1 5 16 13 18 — 0 2 1 — — 1 4 1 4
Oregon§ — 8 16 12 27 — 0 1 — — — 1 31 8 33
Washington 9 10 46 10 3 — 2 12 — — 1 2 13 3 3
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U
Guam — 0 0 — — N 0 0 N N — 0 0 — —
Puerto Rico — 11 47 2 9 — 0 0 — — — 0 6 — 1
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U UVol. 56 / No. 4 MMWR 87
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. †
Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by S. pneumoniae, which is susceptible or for which susceptibility testing is not available
(NNDSS event code 11717). §
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
Streptococcus pneumoniae, invasive disease†
Streptococcal disease, invasive, group A Age <5 years
Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006
United States 62 84 216 237 398 13 24 60 68 69
New England —3 1 56 1 6 —1422
Connecticut — 0 0 — — — 0 0 — —
Maine§ —0212 —02 — —
Massachusetts — 1 5 — 13 — 0 4 — 2
N e w  H a m p s h i r e —0911 —041 —
Rhode Island§ —02 — — —03 — —
Vermont§ —024 — —011 —
Mid. Atlantic 81 74 03 78 4 3 31 31 21 2
New Jersey — 2 8 — 18 — 1 4 — 6
New York (Upstate) 6 5 22 14 12 3 2 13 12 5
New York City — 2 8 3 21 — 0 2 — 1
Pennsylvania 2 6 13 20 33 N 0 0 N N
E.N. Central 13 13 46 51 93 3 6 14 17 20
Illinois — 2 12 5 37 — 1 6 — 4
Indiana 2 2 11 5 2 2 0 10 2 —
M i c h i g a n —3 1 28 2 3 —1586
O h i o 1 14 1 9 3 3 2 4 12766
W i s c o n s i n —14 —7 —0214
W.N. Central 6 5 57 19 23 1 2 10 6 3
Iowa — 0 0 — — — 0 0 — —
Kansas 3135 1 3 —0322
Minnesota — 0 52 — — — 1 7 — —
Missouri 3 1 5 12 4 10241
Nebraska§ —04 —6 —02 — —
North Dakota — 0 2 — — — 0 1 — —
South Dakota — 0 2 2 — — 0 0 — —
S. Atlantic 18 22 45 61 96 1 1 7 15 9
Delaware — 0 2 — 1 — 0 0 — —
District of Columbia — 0 2 — 3 — 0 1 — —
F l o r i d a 7 51 61 92 6 — 0 1 1—
Georgia 4 5 12 15 27 — 0 2 5 —
Maryland§ 44 1 2 1 7 1 7 —1578
North Carolina — 0 26 — 5 — 0 0 — —
South Carolina§ —1659 —011 —
Virginia§ 32958 1001 —
West Virginia — 0 6 — — — 0 2 — 1
E.S. Central 13 1 17 1 6 —02 —3
Alabama§ N00NN N00NN
K e n t u c k y 10542 —00 — —
Mississippi N 0 0 N N — 0 2 — 3
Tennessee§ —293 1 4 —00 — —
W.S. Central 6 7 18 15 24 2 4 28 6 7
Arkansas§ 10521 10212
Louisiana — 0 2 — — — 0 1 1 —
Oklahoma 2288 1 2 11 1 235
Texas § 34 1 45 1 1 —2 1 31 —
Mountain 91 14 23 73 4 3 31 21 01 3
A r i z o n a 35 3 4 1 2 1 0 22988
C o l o r a d o 427 1 3 1 1 11414
Idaho§ —0111 —01 — —
Montana§ N00NN N00NN
Nevada§ —03 — — —00 — —
New Mexico§ —1553 —0311
U t a h 21558 —00 — —
Wyoming§ —0111 —00 — —
Pacific 1294 1 2 —01 — —
Alaska — 0 1 1 N — 0 0 — —
California N 0 0 N N N 0 0 N N
H a w a i i 1293 1 2 —01 — —
Oregon§ N00NN N00NN
Washington N 0 0 N N N 0 0 N N
American Samoa U 0 0 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U
Guam — 0 0 — — N 0 0 N N
Puerto Rico — 0 0 — — N 0 0 N N
U.S. Virgin Islands U 0 0 U U U 0 0 U U88 MMWR February 2, 2007
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. †
Includes cases of invasive pneumococcal disease caused by drug-resistant S. pneumoniae (DRSP) (NNDSS event code 11720).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
United States 44 45 96 206 250 6 6 18 23 26 125 177 231 418 618
New England — 0 3 2 1 — 0 1 — 1 5 3 10 11 15
Connecticut — 0 0 — — — 0 0 — — — 0 6 — —
Maine§ —0 2— — —0 1— — — 02— 1
Massachusetts — 0 0 — — — 0 0 — — 2 2 7 7 11
New Hampshire — 0 0 — — — 0 0 — — 3 0 2 4 3
Rhode Island§ —0 2— — —0 1— — — 02——
Vermont§ —0 2 2 1 —0 1—1 — 01——
Mid. Atlantic 4 3 8 21 13 1 0 3 4 1 23 23 35 83 56
New Jersey — 0 0 — — — 0 0 — — 5 3 8 9 10
New York (Upstate) 1 1 5 3 2 1 0 2 1 — — 3 9 5 4
New York City — 0 0 — — — 0 0 — — 18 11 23 52 32
Pennsylvania 3 2 6 18 11 — 0 2 3 1 — 5 12 17 10
E.N. Central 19 10 39 73 53 3 1 7 7 6 14 15 32 31 82
Illinois — 0 2 — 4 — 0 1 — — — 7 13 1 54
Indiana 3 2 23 12 3 — 0 5 — — 1 1 5 2 9
Michigan — 0 3 — 5 — 0 1 — — 4 2 10 10 1
O h i o 1 6 53 7 6 1 4 1 3 15 7 6 7 3 81 41 5
Wisconsin N 0 0 N N — 0 0 — — 2 1 4 4 3
W.N. Central 1 1 51 6 5 — 0 10 1 1 3 5 13 9 18
Iowa — 0 0 — — — 0 0 — — — 0 3 — 1
Kansas — 0 0 — — — 0 0 — — — 0 3 1 3
Minnesota — 0 50 — — — 0 10 — — — 0 2 3 4
Missouri 1 1 2 6 5 — 0 1 — 1 3 3 8 5 10
Nebraska§ —0 1— — —0 0— — — 02——
North Dakota — 0 0 — — — 0 0 — — — 0 1 — —
South Dakota — 0 3 — — — 0 1 1 — — 0 3 — —
S. Atlantic 20 21 45 90 145 2 2 8 11 8 43 41 78 145 126
Delaware — 0 0 — — — 0 0 — — 1 0 3 1 4
District of Columbia — 0 3 — 3 — 0 2 — — 6 2 7 10 8
F l o r i d a 1 01 2 2 9 4 9 4 7 2 2 8 1 1 8 2 2 1 52 3 6 8 5 6
Georgia 10 7 28 39 93 — 0 1 — — — 7 48 — —
Maryland§ — 0 0 — — — 0 0 — — 6 5 14 25 19
North Carolina — 0 0 — — — 0 0 — — 1 5 20 23 24
South Carolina§ —0 0— — —0 0— — 2 15 8 5
Virginia§ N 0 0 N N — 0 0 — — 5 3 17 10 10
West Virginia — 1 14 2 2 — 0 1 — — — 0 2 — —
E.S. Central —2 1 1 41 6 —0 2—3 8 1 4 2 9 3 7 3 1
Alabama§ N 0 0 N N — 0 0 — — 3 6 18 12 13
Kentucky — 0 3 2 5 — 0 2 — — 1 1 9 7 5
Mississippi — 0 0 — — — 0 0 — — — 1 8 — 3
Tennessee§ — 2 10 2 11 — 0 2 — 3 4 5 13 18 10
W.S. Central — 0 5 8 2 — 0 2 — — 16 28 54 59 94
Arkansas§ —0 3— 2 —0 2— — 1 16 3 1
Louisiana — 0 2 — — — 0 1 — — 5 4 27 9 4
Oklahoma — 0 4 8 — — 0 0 — — 3 1 4 9 3
Texas § —0 0— — —0 0— — 7 2 0 3 4 3 8 8 6
Mountain —1 7 21 5 —0 5—6 9 8 2 6 1 5 2 5
Arizona — 0 0 — — — 0 0 — — 9 3 16 10 9
Colorado — 0 0 — — — 0 0 — — — 1 5 — 5
Idaho§ N0 0 N N —0 0— — — 01— 1
Montana§ —0 0— — —0 0— — — 01——
Nevada§ —0 2 1 2 —0 1— — — 1 1 2— 8
New Mexico§ —0 0— — —0 0— — — 15 5 2
U t a h —0 7—1 1 —0 4—6 — 02——
Wyoming§ —1 3 1 2 —0 2— — — 00——
Pacific —0 0— — —0 0— — 4 3 6 5 0 2 8 1 7 1
Alaska — 0 0 — — — 0 0 — — — 0 4 — —
California N 0 0 N N — 0 0 — — 2 32 43 22 148
Hawaii — 0 0 — — — 0 0 — — — 0 2 — 1
Oregon§ N0 0 N N —0 0— — — 06 1 2
Washington N 0 0 N N — 0 0 — — 2 2 11 5 20
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U
Guam N 0 0 N N — 0 0 — — — 0 0 — —
Puerto Rico N 0 0 N N — 0 0 — — 4 3 10 10 8
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
Streptococcus pneumoniae, invasive disease, drug resistant†
All ages Age <5 years Syphilis, primary and secondary
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006Vol. 56 / No. 4 MMWR 89
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending January 27, 2007, and January 28, 2006
(4th  Week)*
                                                                                     West Nile virus disease†
Varicella (chickenpox) Neuroinvasive Non-neuroinvasive§
Previous Previous Previous
Current 52 weeks   Cum Cum Current 52 weeks Cum Cum Current 52 weeks  Cum Cum
Reporting area week Med Max 2007 2006 week Med Max 2007 2006 week Med Max 2007 2006
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.         —: No reported cases.         N: Not notifiable.         Cum: Cumulative year-to-date counts.         Med: Median.         Max: Maximum.
* Incidence data for reporting years 2006 and 2007 are provisional. †Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET
Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I. §Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2004 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶
Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
United States 427 837 1,432 2,206 3,167 — 1 178 — 2 — 1 399 — —
New England 62 8 5 9 3 91 7 3 — 0 3 —— —0 2 — —
Connecticut — 0 0 — — — 0 3 — — — 0 1 — —
Maine¶ —0 1 6 —3 8 —0 0— — — 00——
Massachusetts — 0 17 — 46 — 0 1 — — — 0 1 — —
New Hampshire 4 6 47 18 28 — 0 0 — — — 0 0 — —
Rhode Island¶ —0 0 — — —0 0— — — 00——
Vermont¶ 21 2 5 0 2 1 6 1 — 0 0 —— —0 0 — —
Mid. Atlantic 122 106 180 472 533 — 0 11 — — — 0 4 — —
New Jersey N 0 0 N N — 0 2 — — — 0 1 — —
New York (Upstate) N 0 0 N N — 0 5 — — — 0 1 — —
New York City — 0 0 — — — 0 4 — — — 0 2 — —
Pennsylvania 122 106 180 472 533 — 0 2 — — — 0 1 — —
E.N. Central 70 312 602 878 1,422 — 0 43 — — — 0 33 — —
Illinois — 1 7 — 8 — 0 23 — — — 0 23 — —
Indiana — 0 0 — — — 0 7 — — — 0 12 — —
Michigan 70 111 250 395 443 — 0 11 — — — 0 2 — —
Ohio — 156 420 478 745 — 0 11 — — — 0 3 — —
Wisconsin — 15 142 5 226 — 0 2 — — — 0 2 — —
W.N. Central 17 30 98 108 254 — 0 36 — — — 0 79 — —
Iowa N 0 0 N N — 0 3 — — — 0 4 — —
Kansas 7 4 24 30 62 — 0 3 — — — 0 3 — —
Minnesota — 0 0 — — — 0 6 — — — 0 7 — —
Missouri 9 22 82 68 182 — 0 14 — — — 0 2 — —
Nebraska¶ N0 0 N N —0 9— — — 0 3 8——
North Dakota — 0 8 — — — 0 5 — — — 0 28 — —
South Dakota 1 1 15 10 10 — 0 7 — — — 0 22 — —
S. Atlantic 45 83 223 183 225 — 0 2 — — — 0 7 — —
D e l a w a r e — 1 657 — 0 0 — — — 0 0 — —
District of Columbia — 0 5 — 1 — 0 0 — — — 0 1 — —
Florida N 0 22 N N — 0 1 — — — 0 0 — —
Georgia N 0 0 N N — 0 1 — — — 0 4 — —
Maryland¶ N0 0 N N —0 2— — — 02——
North Carolina — 0 0 — — — 0 1 — — — 0 0 — —
South Carolina¶ 41 6 5 3 2 7 6 8 — 0 1 —— —0 0 — —
Virginia¶ —2 8 1 3 3 1 5 — 0 0 —— —0 2 — —
West Virginia 41 28 70 150 144 — 0 1 — — — 0 0 — —
E.S. Central 5 4 43 29 — — 0 15 — 2 — 0 16 — —
Alabama¶ 5 4 43 28 — — 0 2 — — — 0 0 — —
Kentucky N 0 0 N N — 0 2 — — — 0 1 — —
Mississippi — 0 1 1 — — 0 10 — 2 — 0 16 — —
Tennessee¶ N0 0 N N —0 4— — — 02——
W.S. Central 92 194 556 307 312 — 0 58 — — — 0 26 — —
Arkansas¶ —1 4 8 8 6 4 1 — 0 4 —— —0 2 — —
Louisiana 2 1 8 11 1 — 0 13 — — — 0 9 — —
Oklahoma — 0 0 — — — 0 6 — — — 0 4 — —
Texas ¶ 90 170 549 290 270 — 0 38 — — — 0 16 — —
Mountain 70 61 137 189 248 — 0 61 — — — 1 228 — —
Arizona — 0 0 — — — 0 9 — — — 0 15 — —
Colorado 21 28 76 69 180 — 0 10 — — — 0 51 — —
Idaho¶ N 0 0 N N — 0 30 — — — 0 157 — —
Montana¶ 10 0 7 28 N — 0 3 — — — 0 8 — —
Nevada¶ —0 3 — 1 —0 9— — — 0 1 6——
New Mexico¶ — 4 34 12 19 — 0 1 — — — 0 1 — —
Utah 39 16 65 80 46 — 0 8 — — — 0 17 — —
Wyoming¶ —1 1 1 — 2 —0 7— — — 0 1 0——
Pacific —0 1 1 — —0 1 5— — — 0 5 1——
Alaska — 0 1 1 N — 0 0 — — — 0 0 — —
California — 0 0 — N — 0 15 — — — 0 37 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon¶ N0 0 N N —0 2— — — 0 1 4——
Washington N 0 0 N N — 0 0 — — — 0 2 — —
American Samoa U 0 0 U U U 0 0 U U U 0 0 U U
C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 10 30 3 19 — 0 0 — — — 0 0 — —
U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U90 MMWR February 2, 2007
TABLE III. Deaths in 122 U.S. cities,* week ending January 27, 2007 (4th Week)
All causes, by age (years) All causes, by age (years)
All P&I† All P&I†
Reporting Area Ages >65 45-64 25-44 1-24 <1 Total Reporting Area Ages >65 45-64 25-44 1-24 <1 Total
U: Unavailable.          —:No reported cases.
*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its
occurrence and by the week that the death certificate was filed. Fetal deaths are not included.
†Pneumonia and influenza.
§Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.
**Total includes unknown ages.
New England 584 414 115 22 18 15 52
Boston, MA 128 86 26 4 8 4 17
Bridgeport, CT 30 20 7 1 2 — 4
Cambridge, MA 15 13 2 — — — 1
Fall River, MA 30 23 4 2 1 — 1
Hartford, CT 64 50 8 2 3 1 9
Lowell, MA 24 15 7 1 — 1 1
Lynn, MA 7 5 1 1 — — 2
New Bedford, MA 24 18 5 1 — — 1
New Haven, CT 55 31 17 2 3 2 6
Providence, RI 72 46 16 6 1 3 5
Somerville, MA 2 2 — — — — —
Springfield, MA 36 29 4 1 — 2 —
Waterbury, CT 37 26 10 1 — — 5
Worcester, MA 60 50 8 — — 2 —
Mid. Atlantic 2,046 1,427 452 90 36 39 113
Albany, NY 43 35 6 1 1 — —
Allentown, PA 21 14 4 1 1 1 —
Buffalo, NY 84 55 25 3 1 — 6
Camden, NJ 31 22 6 2 — 1 2
Elizabeth, NJ 23 16 3 2 1 1 3
Erie, PA 61 44 15 — 1 1 4
Jersey City, NJ U U U U U U U
New York City, NY 1,111 761 266 50 13 19 53
Newark, NJ 33 15 9 4 1 4 —
Paterson, NJ U U U U U U U
Philadelphia, PA 162 101 37 12 7 5 12
Pittsburgh, PA§ 35 25 7 1 — 2 —
Reading, PA 43 31 6 2 3 1 3
Rochester, NY 159 121 25 8 2 3 15
Schenectady, NY 19 15 3 — 1 — —
Scranton, PA 22 17 4 — 1 — 2
Syracuse, NY 126 99 21 2 3 1 7
Trenton, NJ 29 21 7 1 — — —
Utica, NY 22 18 4 — — — 3
Yonkers, NY 22 17 4 1 — — 3
E.N. Central 2,101 1,411 464 134 45 47 161
Akron, OH U U U U U U U
Canton, OH 39 26 8 4 — 1 7
Chicago, IL 369 230 82 34 13 10 36
Cincinnati, OH 79 63 11 4 1 — 13
Cleveland, OH 252 176 54 15 1 6 11
Columbus, OH 229 155 55 10 4 5 20
Dayton, OH 127 95 21 5 3 3 9
Detroit, MI 168 78 60 17 8 5 8
Evansville, IN 43 32 10 1 — — 2
Fort Wayne, IN 53 41 9 1 1 1 6
Gary, IN 16 9 3 3 1 — —
Grand Rapids, MI 64 44 11 6 — 3 3
Indianapolis, IN 201 128 49 16 2 6 17
Lansing, MI 55 39 11 4 — 1 3
Milwaukee, WI 94 61 26 2 2 3 8
Peoria, IL 48 35 8 1 3 1 2
Rockford, IL 62 41 15 3 3 — 3
South Bend, IN 58 47 8 1 1 1 3
Toledo, OH 101 79 17 4 — 1 8
Youngstown, OH 43 32 6 3 2 — 2
W.N. Central 683 461 137 43 20 19 51
Des Moines, IA 35 29 3 2 — 1 8
Duluth, MN 21 15 6 — — — —
Kansas City, KS 24 13 5 5 1 — 1
Kansas City, MO 106 74 22 3 4 2 5
Lincoln, NE 42 30 9 2 — 1 5
Minneapolis, MN 77 48 16 8 1 4 4
Omaha, NE 110 83 17 6 1 3 9
St. Louis, MO 94 54 22 7 7 2 4
St. Paul, MN 67 44 12 5 1 5 6
Wichita, KS 107 71 25 5 5 1 9
S. Atlantic 1,505 939 369 127 41 29 82
Atlanta, GA 296 171 77 35 6 7 13
Baltimore, MD 213 122 58 20 6 7 20
Charlotte, NC 118 82 20 11 2 3 12
Jacksonville, FL 166 108 41 11 4 2 7
Miami, FL 116 78 23 7 8 — 4
Norfolk, VA 65 37 16 5 3 4 2
Richmond, VA 69 42 23 4 — — 3
Savannah, GA 69 44 19 4 — 2 3
St. Petersburg, FL 51 32 5 4 7 3 4
Tampa, FL 199 136 46 11 5 1 12
Washington, D.C. 125 76 38 11 — — —
Wilmington, DE 18 11 3 4 — — 2
E.S. Central 1,055 676 249 69 33 28 98
Birmingham, AL 213 133 52 14 6 8 25
Chattanooga, TN 82 57 16 4 2 3 6
Knoxville, TN 127 82 31 8 4 2 11
Lexington, KY 66 53 12 — 1 — 5
Memphis, TN 186 116 48 12 7 3 25
Mobile, AL 121 79 22 13 6 1 5
Montgomery, AL 80 48 24 4 1 3 4
Nashville, TN 180 108 44 14 6 8 17
W.S. Central 1,967 1,266 472 130 58 41 124
Austin, TX 100 63 23 9 3 2 8
Baton Rouge, LA 85 58 20 4 3 — —
Corpus Christi, TX 123 77 24 11 7 4 16
Dallas, TX 270 159 79 20 8 4 23
El Paso, TX 95 71 17 4 2 1 4
Fort Worth, TX 132 98 28 2 2 2 12
Houston, TX 494 292 131 41 19 11 19
Little Rock, AR 70 45 17 5 1 2 2
New Orleans, LA¶ UUUU U U U
San Antonio, TX 362 238 78 26 11 9 24
Shreveport, LA 78 53 18 5 — 2 9
Tulsa, OK 158 112 37 3 2 4 7
Mountain 1,220 788 264 81 48 36 77
Albuquerque, NM 133 81 36 10 3 3 7
Boise, ID 54 39 9 5 1 — 3
Colorado Springs, CO 55 41 10 2 — 2 2
Denver, CO 123 62 36 5 6 14 5
Las Vegas, NV 289 185 61 23 11 9 16
Ogden, UT 44 23 15 4 1 1 5
Phoenix, AZ 227 143 45 17 15 4 13
Pueblo, CO 36 28 6 1 1 — 6
Salt Like City, UT 119 78 29 7 4 1 11
Tucson, AZ 140 108 17 7 6 2 9
Pacific 1,583 1,111 339 70 33 29 147
Berkeley, CA 14 9 3 — — 2 —
Fresno, CA U U U U U U U
Glendale, CA U U U U U U U
Honolulu, HI 80 58 13 1 4 4 6
Long Beach, CA 95 58 24 8 1 4 19
Los Angeles, CA U U U U U U U
Pasadena, CA 27 20 2 2 1 1 6
Portland, OR 142 97 35 5 5 — 12
Sacramento, CA 263 179 65 10 5 4 24
San Diego, CA 179 126 28 10 6 9 12
San Francisco, CA 134 99 25 8 1 1 10
San Jose, CA 256 188 53 10 2 3 30
Santa Cruz, CA 36 27 9 — — — 3
Seattle, WA 124 79 33 8 4 — 10
Spokane, WA 81 61 17 1 1 1 8
Tacoma, WA 152 110 32 7 3 — 7
Total 12,744** 8,493 2,861 766 332 283 905Vol. 56 / No. 4 MMWR 91
Notifiable Disease Data Team and 122 Cities Mortality Data Team
Patsy A. Hall
Deborah A. Adams Rosaline Dhara
Willie J. Anderson Vernitta Love
Lenee Blanton Pearl C. Sharp
* No measles cases were reported for the current 4-week period, yielding a ratio for week 4 of zero (0).
†Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week
periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard
deviations of these 4-week totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of
provisional 4-week totals January 27, 2007, with historical data
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